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ABSTRACT OF DISSERTATION
REEVALUATION OF THE AAPM TG-43 BRACHYTHERAPY DOSIMETRY
PARAMETERS FOR AN 125I SEED, AND THE INFLUENCE OF EYE PLAQUE DESIGN
ON DOSE DISTRIBUTIONS AND DOSE-VOLUME HISTOGRAMS
The TG-43 dosimetry parameters of the AdvantageTM 125I model IAI-125A
brachytherapy seed were studied. An investigation using modern MCNP radiation
transport code with updated cross-section libraries was performed. Twelve different
simulation conditions were studied for a single seed by varying the coating thickness,
mass density, photon energy spectrum and cross-section library. The dose rate was
found to be 6.3% lower at 1 cm in comparison to published results. New TG-43
dosimetry parameters are proposed.
The dose distribution for a brachytherapy eye plaque, model EP917, was
investigated, including the effects of collimation from high-Z slots. Dose distributions for
26 slot designs were determined using Monte Carlo methods and compared between
the published literature, a clinical treatment planning system, and physical
measurements.
The dosimetric effect of the composition and mass density of the gold backing
was shown to be less than 3%. Slot depth, width, and length changed the central axis
(CAX) dose distributions by < 1% per 0.1 mm in design variation. Seed shifts in the slot
towards the eye and shifts of the 125I-laden silver rod within the seed had the greatest
impact on the CAX dose distribution, changing it by 14%, 9%, 4.3%, and 2.7% at 1, 2, 5,
and 10 mm, respectively, from the inner scleral surface.
The measured, full plaque slot geometry delivered 2.4% ± 1.1% higher dose
along the plaque’s CAX than the geometry provided by the manufacturer and
2.2%±2.3% higher than Plaque SimulatorTM (PS) treatment planning software (version
5.7.6). The D10 for the simulated tumor, inner sclera, and outer sclera for the measured
slot plaque to manufacturer provided slot design was 9%, 10%, and 19% higher,
respectively. In comparison to the measured plaque design, a theoretical plaque having
narrow and deep slots delivered 30%, 37%, and 62% lower D10 doses to the tumor,
inner sclera, and outer sclera, respectively. CAX doses at –1, 0, 1, and 2 mm were also
lower by a factor of 2.6, 1.72, 1.50, and 1.39, respectively. The study identified
substantial sensitivity of the EP917 plaque dose distributions to slot design.
KEYWORDS: Monte Carlo methods, dosimetry, 125I, TG-43, eye plaque brachytherapy
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CHAPTER 1 INTRODUCTION

1.1 General Introduction
A tumor can be benign or malignant. Cancer is a type of tumor characterized by
overgrowth of abnormal cells which grow by dividing to make new cells. Their ability to
metastasize distinguishes them from other tumor cells. There are many different types
of cancer and each is unique in how it grows and responds to treatment. One way to
stop the cancer from growing is to interfere with the cancer cell’s ability to multiply.
Radiation, used at high doses, causes changes in the cancer cell that affect the ability
to reproduce and eventually leads to cell death.
Low energy photons (e.g., 20 keV to 150 keV) can be used for the diagnosis of
patient disease or for the treatment of cancerous tumor, while high energy photons
(e.g., 1 MeV to 20 MeV) are used to kill cancer cells. Radiation therapy, like surgery,
chemotherapy and biological therapy, is one modality to treat cancer. The radiation can
come from radioactive substances or linear accelerators. The treatment of cancer by
linear accelerators is termed external beam radiation therapy, while treatment of cancer
by encapsulated radioactive substances (sources) is called brachytherapy. A patient
may receive radiation therapy in conjunction with other cancer treatment but more than
half of the patients with cancer receive radiation therapy either by external beam
radiation therapy or brachytherapy or both. 1
Brachytherapy is a treatment modality using encapsulated sealed radiation
sources. The treatment is given by placing the sources directly into the tumor volume or
close to the tumor volume. There are two types of radionuclide sources used in
brachytherapy. The first type is short lived with low energy. These radionuclides,

1

including

125

I,

103

Pd, and131Cs, are used to treat cancer by placing them in the tumor

volume permanently. The second type of radionuclide is long lived sources with higher
energy. These radionuclides including

137

Cs,

60

Co, and

192

Ir are used for temporary

brachytherapy implants. Most brachytherapy treatments are from photon emitting
radionuclides; however beta and neutron emitting radionuclides are also used.
Brachytherapy can be used for many types of cancer. Some common cancers
treated with brachytherapy include prostate, breast, lung, esophageal, gynecologic,
anal/rectal, sarcomas, eye as well as head and neck. 2 Low dose rate (LDR)
brachytherapy treatment uses low strength radioactive sources 3. The treatment time is
normally longer and is most commonly used to treat prostate and gynecological
cancers. The practice in brachytherapy has been changed with the advancement of
technology and imaging modalities for target localization, and for planning and
optimizing the proposed geometry. Figure 1.1 shows imaging modalities used for LDR
prostate brachytherapy and Figure 1.2 shows an LDR prostate treatment plan using
ultrasound imaging.

2

Figure 1.1 Imaging modalities used for prostate LDR brachytherapy.

3

Figure 1.2 Ultrasound image used for prostate LDR brachytherapy computerized
treatment planning.

High dose rate (HDR) brachytherapy treatment uses high strength (e.g., 10 Ci)
radioactive sources contained within an after loading device. The designated catheters
and transfer guide tubes are attached to applicators and the HDR unit. The applicators
are placed in the patient during patient simulation. The unit can be operated to send an
active radioactive source wire to catheters which are attached to the applicator devices
to deliver the radiation dose to the tumor. The source remains for short periods of time
in each position based on the treatment plan produced. HDR treatment usually takes 520 minutes for most of the gynecological cancers.

4

HDR treatment has become popular for delivering the desired radiation dose to
the tumor in just a few minutes. This may also be a comfort to patients who, in some
cases, require less hospitalization. However; multiple treatments are required to reduce
the radiation toxicity to normal tissues. Figure 1.3 shows two HDR brachytherapy units.

Figure 1.3 HDR after loader units. The unit on the left is from NucletronTM (Netherlands)
and on the right is the unit from Varian Medical SystemsTM (California, USA)

1.2 Motivation
Many

authors

have

independently

characterized

commercially produced brachytherapy sources.12,13,18,19,53

various

low-energy;

125

I radioactive seed has been

widely used for permanent brachytherapy. The dosimetry of these low energy sources is
well documented in AAPM task group reports published in 1995, 2004, and 2007.4,5,14

5

The dose calculation is determined with dosimetry parameters such as air-kerma
strength, dose rate constant, radial dose function, geometry function, and anisotropy
function as described in series of AAPM task group (TG) 43 reports. However, one
method used to calculate these consensus dosimetric parameter values was based on
a previous Monte Carlo algorithm. The algorithm has been revised and updated since
the publication of these AAPM reports in 2004 and 2007. 4,5 But the consensus data for
low energy photon emitting radionuclides has yet to be reviewed based on the updated
methodology. Therefore, one motivation of this project is to obtain the values of
dosimetric parameters in the TG-43 reports. 4,5,14 Of the

125

I seed models, the IsoAid

Advantage I-125™ Seed (model IAI-125A), was selected for this study.
Intraocular tumors have been treated for many years with
Different gold eye plaques with silastic inserts for the

125

I brachytherapy.

125

I seeds are now available

commercially. These Collaborative Ocular Melanoma Study (COMS) plaques come with
various circular diameter sizes 8 mm, 12 mm, 14 mm, 18 mm, and 22 mm. COMS
plaques with notches are used to limit the dose to critical structures. However, these
plaques are not suitable to treat elongated and asymmetrical superficial ocular tumors.
These superficial ocular tumors are normally 1 mm to 5 mm deep. Moreover, these are
associated with uncertainties with seed carriers (silastic). Therefore, researchers at the
University of Southern California (USC) designed a plaque to overcome these issues.
This study is focused on the elongated EP917 (USC #9) plaque where radioactive
seeds are embedded directly in to the slots of the plaque. The radiation dose tolerance
of superficial eye structures such as the sclera has also been an issue. Therefore, this
study also focuses on reconstructing the EP917 plaque and quantifying the effect of
attenuation and back scatter from the gold backing and its collimation.

6

1.3 Proposed Study
The consensus data of TG-43 parameters are based on Monte Carlo (MC)
calculations and experimental methods. 4,5,14 Most brachytherapy treatment planning
systems have adopted the TG-43 formalism. The MCNP5 code for radiation transport
simulation has been revised and updated to include photon cross section libraries,
variance reduction techniques and other improvements since its original publication in
1987. But we continued to rely on outdated consensus data in which the brachytherapy
treatment planning systems are commissioned for brachytherapy dose calculation.
Therefore, the principal aim of this study is to determine and investigate dosimetric
parameters of the TG-43 report with revised and updated Monte Carlo version 5
(MCNP5) dose calculation algorithm for an

125

I seed (model IAI-125A). The seed was

fully modeled, redesigned and thoroughly investigated. In our study, we incorporated
the most recent manufacturer’s seed information and previous authors’ early works. All
AAPM TG-43 reports recommendations were also properly followed.

1.4 Dissertation Outline
The dissertation consists of five chapters. In Chapter 1, a brief overview of
cancer, radiation therapy, and brachytherapy is discussed. Chapter 2 presents the
interaction of radiation with matter, an introduction of Monte Carlo simulations, and
brachytherapy radiation dose calculation methods. Chapter 3 presents the investigation
of TG-43 dosimetry parameters for a particular model of

125

I seed including the

recommendation to use our new proposed dosimetry parameters. The contents of this
chapter were published in Medical Physics.65 In this work, the source characteristics of
125

I (model IAI-125A), MC simulation techniques, calculation of TG-43 dosimetry

parameters, and an uncertainty analysis are described. Chapter 4 provides independent

7

dosimetric assessment of the model EP917 episcleral brachytherapy plaque. The
contents of this chapter have also been submitted to Medical Physics. This chapter
includes experimental validation of published plaque design as well as an assessment
of variations in single slot and full plaque designs using MC methods. The dosimetric
influence of these variations on tumor and sclera are presented. Chapter 5 presents a
summary and conclusions.

Copyright © Prakash Aryal 2014
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CHAPTER 2 THEORETICAL BACKGROUND

2.1 Radiation Interactions with Matter
125

I emits characteristic X-rays (3.77 keV to 31.704 keV) and gamma rays (35.49

keV). The photons in general are indirect ionizing radiation and undergo Rayleigh
scattering, as well as the photoelectric effect, Compton scattering, and pair production
interaction processes to transfer their energy to the medium. Photoelectric effect and
Compton scattering interactions are the most dominant radiological interactions in
brachytherapy.
2.1.1 Raleigh (coherent) Scattering
Raleigh scattering occurs when the photon interacts with the entire atom. This
process is also called Coherent scattering. This is an elastic interaction and the photon
does not lose energy. In this process, the atom oscillates in phase due to the
electromagnetic wave energy of the incident photon. The photon energy absorbed
induces a vibration of the atom. The vibrating atom then de-excites and emits an
equivalent amount of energy. The photon is scattered with a small angle, and in a
slightly different direction but with same wavelength. No ionization occurs in this
interaction since electrons have not been ejected from an atom. Figure 2.1 shows the
Raleigh scattering process. 6

9

Figure 2.1 Rayleigh scattering process. The incident photon with wavelength λ1 interacts
with an atom. The scattered photon with wavelength λ2 is emitted with approximately
same wavelength and energy. Courtesy from J.T. Bushberg et. al.

The momentum is also conserved in this process. The cross-section per atom in this
process is given by:7

�= �
σa,R ∝

z 2 cm2
�atom�
� �
hν

(2.1)

The equation (2.1) can be multiplied by number of atoms per gram to obtain the
macroscopic cross-section and is given by:

10

σR
z
2
� = 2 �cm �g�
∝
hυ
ρ

(2.2)

Therefore, the macroscopic cross-section per unit mass is directly proportional to
atomic number of an atom and inversely proportional to square of the energy of the
photon. Raleigh scattering occurs at very low energies and there is no energy
transferred to the medium. As such, this process has no role in radiation dosimetry. 7

2.1.2 Photoelectric Effect
In the photoelectric process, the incident photon interacts with a tightly bound,
inner shell electron (usually the K shell) of an atom. The photon is completely absorbed
and an electron (called photoelectron) is emitted with kinetic energy (Ee) equal to the
photon energy, (E0=hν), minus the orbital binding energy (Eb) assuming that kinetic
energy imparted to the recoiling atom is nearly zero.

Ee = E0 − Eb

(2.3)
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Figure 2.2 Photoelectric interaction processes. In the photoelectric process, the incident
x-ray photon collides with a low energy (in this case, K-shell) orbital electron and
transfers all of its energy to that electron. The photoelectric event is followed by a
subsequent cascade of electron transitions from higher- to lower energy orbitals to fill
the vacated positions, which results emission of characteristic radiation
(en.wikibooks.org).
The photoelectric process occurs when the incident photon energy is greater
than the binding energy of the orbital electron. The vacancy created by the ejected
electron is filled by the higher orbital electrons. The probability of a photoelectric
interaction depends on the medium and photon energy. The photoelectric cross-section
per atom is given by
7

32
me c 2 2
στ =
�
√2πre2 ά 4 Z 5 �
3
E0

(2.4)

(Fundamentals of PET SPECT M. Wernick, J. Aarsvold, 2004)

Where 32/3 √2πre2 ά 4 is a constant of proportionality, 𝑟𝑒 is the classical electron radius,
Z is the atomic number of the medium, and E0 is the energy of incident photon. When
12

E0 is near K, L, M shell binding energy, the equation (2.4) needs to be multiplied by
correction factor (1/Z2)(mec2/E0)1/2 to accounts for quantum effects. This increases the
cross-section near E0 = Eb which creates sharp discontinuity called absorption edge.
Therefore,

στ ∝

𝑍3

(2.5)

𝐸40

Photoelectric absorption is a dominant interaction for low energy photons (keV)
and high atomic number materials. The probability of photoelectric interaction
decreases with increasing photon energy. Sharp discontinuities called absorption edges
exist for high Z materials like titanium, silver, and gold (Figure 2.4). The probability of
interaction is greater for photons with energies just above the absorption edge than
those with energies just slightly below the edge.

2.1.3 Compton (incoherent) Scattering)
Compton scattering is inelastic or non-classical scattering, and is the
predominant interaction for brachytherapy radiation in tissue. In this process, the
incident photon interacts with energy , Eγ , greater than the binding energy of a loosely

bound outer shell electron.

Eγ = Eγ′ + Ee−

(2.6)

Here 𝐸𝛾 is the incident energy of the photon, 𝐸𝛾′ is the energy of scattered photon, and

𝐸𝑒 − is the energy of an ejected electron.
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Figure 2.3 The Compton scattering process, where, the incident photon is scattered by
a free electron at an angle ϕ. The Compton electron carries energy T in its direction of
scatter by an angle θ. Energy and momentum are conserved in the interaction. 7

The energy of the scattered photon is given by:7

hν′ =

hν

hν
(1 − cosϕ)
1+
m0 c 2

(2.7)

The kinetic energy of the recoil electron is T= ℎ𝜈 − ℎ𝜈 ′ . The electron is ejected at an
angle, θ

cotθ = �1 +

hν
ϕ
� tan � �2�
m0 c 2

(2.8)

Where ϕ is the angle of the scattered photon.The binding energy of the ejected electron
is comparatively small and can be ignored for the range of energy used in our study.
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2.1.4 Processes Relevant to the Current Work
Most of the photon emitting brachytherapy sources emit poly-energic spectra in
the range of 21 keV to 662 keV. The mean energy of the spectrum emitted by the

125

I

radioactive seed model used in this study is about 28 keV. Therefore, photoelectric and
Compton are the two primary, relevant interactions mechanisms that we considered.
To illustrate the relative importance of the potential interaction mechanisms, we
present Fig. 2.4, which displays the linear attenuation coefficients for the media used in
this study. Data are displayed over the range of 1 keV to 100 keV. The photoelectric
effect dominates at energies below 26 keV in soft tissue, while Rayleigh scattering
contributes only 5% to 10% at this energy. When higher energy photons interact with a
low Z material (e.g., tissue), Compton scattering becomes dominant. The low energy
photons

from

125

I produce short range electrons, therefore, can be ignored. The

collision kerma approximates the absorbed dose. The pair production interaction has a
minimum energy of 1.02 MeV and as such, is not relevant within the context of this
study.
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Figure 2.4: Coherent, incoherent, photoelectric, and total linear attenuation coefficients
for (a) water, (b) titanium, (c) silver, and (d) gold as a function of energy. The asorption
edges (the discrete increase in attenuation coefficients) occur due to photoelectric
absorption when photon energy exceeds the binding energy of inner shell electrons (K,
L, M…) thus increasing number of electrons available for interaction. This effect is
significant for high Z material for low energy range( like energy from 125I).
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2.2 Monte Carlo Simulation
The Monte Carlo N-Particle version 5 (MCNP5) is a radiation transport code that
is widely used to simulate the behavior of radiation particles based on the random
statistical nature of their histories. It is a process that simulates transport of photons,
electrons, neutrons, and other particles into a selected media where the nature of
interaction of these particles can be estimated. MCNP5 is particularly useful for complex
problems that cannot be modeled by computer codes that use deterministic methods.
The individual probabilistic events that comprise a process are simulated sequentially.
An input file is created which can be read by the MCNP5 code. It includes cell cards,
surface cards, the description of materials, and selection of cross-sections. The input
file also includes tallies desired for calculation, and variance reduction techniques to
improve efficiency. It is good practice to benchmark and validate the given simulations
using other MC codes and/or measurements. The MCNP5 code performs checks to
ensure that problem geometries, materials, and sources are self-consistent throughout
the input file.
Due to the equivalence between collision kerma and absorbed dose in the
energy range (<300 keV), it is not necessary to simulate the electron histories.
Therefore, we only used photon treatment simulation mode (MODE P) in all simulations.

The general MCNP5 simulation process is given by the following flow chart
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Figure 2.5: Monte Carlo simulation process flow chart. The particle is selected from top
of the stack. If the energy is greater than cutoff energy (<5 keV) it goes through photon
transport process and records event if electron is ejected. If photon is ejected it goes
through series of iteration process until it further ejects electron and records the event.

2.2.1 Physics of MCNP5
The physics of the MCNP5 simulation code is based on the interaction of
neutrons, photons, or electrons. Photoatomic and photonuclear are the two interactions
included in MCNP5. These relate to elemental and isotropic aspects, respectively. The
cross-sectional data of these events are stored in tables separately. The directory file
(XSDIR) is created for each data table and users can select a specific data table by
assigning the atomic number Z, mass number A, and library specifier ID in the form
ZAID. 8
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The Evaluated Nuclear Data File (ENDF) system and the Evaluated Photon Data
Library (EPDL) provide the primary sources of nuclear data.

9

MCNP5 contains nuclear

data tables for neutrons, photons, electrons and neutron-induced photon interactions.
Photon and electron data are mostly atomic in nature but photonuclear data are also
included in MCNP5.
There are two physics photon interaction models used in MCNP5, simple, and
detail. The simple model ignores Raleigh scattering and fluorescent photons from
photoelectric absorption. Therefore, this model is designed for high-energy photon
problems where contribution from photoelectric effect is insignificant. This physics
model uses implicit capture but can be overridden with the CUT:P card.
The detail physics model accounts for fluorescent photons and also includes
Raleigh scattering after photoelectric absorption. The electron binding effects are
accounted for by using Compton profiles and form factors. Analog capture is always
used. The detailed physics treatment uses energy below 100 MeV. All the photon
emitting brachytherapy sources fall into the detail physics treatment category.
The electrons produced from photons are handled in three ways; (1) electron
transport mode turned on (Mode P E), in this case all the photon collisions except
Raleigh (coherent) scatter can create electrons that are stored for later transport; (2)
electron transport mode turned off (Mode P). If a particle which has weight W and
energy E makes a track length or segment T within a specified cell volume, V, then the
segment makes a contribution WTE/V to the energy flux (fluence) to cell. The sum of
the contributions is reported as the *F4 tally in the MCNP output. If ψ(𝑟⃗, E, Ω, t)

represents the angular fluence distribution, then *F4 represents the physical quantity
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∗ F4 = WTE = 1 � 𝑑𝑡 � dV � dE � dΩ 𝐸 ψ(𝑟⃗, E, Ω, t)
V
V
V
E
4π

(2.9)

2.3 TG-43 Dosimetry Formalism Algorithms
Previous formalisms introduced inconsistencies and uncertainties in dose
calculation due to variability in encapsulation or internal structure. Moreover, these
formalisms were based on apparent activity, equivalent mass of radium, exposure rate
constants, and tissue attenuation coefficients. Older formalisms were based on photon
fluence around the source in free space which ignored scattering medium. Accurate
modeling of the anisotropy effect and dose determination in a scattering medium of
brachytherapy sources is almost impossible from the distribution of photon fluence in
free space. 10
The TG-4314 formalism allows two-dimensional dose calculation by introducing
the following dosimetric parameters air-kerma strength, dose-rate constant, radial dose
function, geometry function, and anisotropy function. The last two parameters are a
function of distance and angle. For cylindrically symmetric sources, the two-dimensional
dose rate in a polar coordinate system is given by
𝐷̇(r, θ) = 𝑆𝐾 . Λ .

GL (r, θ)
. g (r) . F(r, θ)
GL (𝑟0 , θ0 ) L
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(2.10)

Figure 2.6 Coordinate system used for brachytherapy dosimetry calculations.

2.3.1 Air-Kerma Strength,SK
The air-kerma strength, SK, is a measure of the strength of a brachytherapy
source and is specified in terms of air-kerma rate at a calibration point along the
transverse axis of the source. It is the product of air-kerma rate,K̇ δ, in vacuo and the

square of the distance, d.

SK = K̇ δ (d)d2

(2.11)

The calibration distance must be large enough that the source may be treated as
a point source. The air kerma rate is measured with the Wide Angle Free Air Chamber
(WAFAC). 11 The measured air-kerma rate is corrected for photon attenuation and
scattering in air and any medium between the source and the detector. The low energy,
𝛿(< 5𝑘𝑒𝑉), photons originating from the outer layer of the steel or titanium source
cladding is excluded because it does not contribute significant dose beyond 0.1 cm in
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tissue. But low energy 3.77 keV of

125

I is included for eye plaque simulations since

sclera of the eye is just a millimeter thick.

2.3.2 Dose-Rate Constant, Λ
The dose-rate constant is defined as the ratio of the dose rate at 1 cm on the
transverse plane in water a 15 cm radius phantom and the air kerma strength.

Λ=

𝐷̇(𝑟0 , 𝜃0 )
𝑆𝐾

(2.12)

The dose-rate constant depends on source model and the radionuclide and is
influenced by source geometry, encapsulation, self-filtration, and the spatial distribution
of radioactivity within the source.14
2.3.3 Geometry Function, G(r,θ)
The geometry function provides an effective inverse square law correction based
upon an approximate model of the spatial distribution of radioactivity within the source
and ignores the photon absorption and scattering within the source. It is the
interpolation between points of calculated or measured dose rates which provides for
approximations with sufficient accuracy in treatment planning applications. However, the
three dimensional distribution of the density of radioactivity of many sources is
uncertain.10 Therefore, the geometry function is explicitly given assuming a point or line
source approximation as recommended by TG-43.

𝐺𝑃(𝑟, 𝜃) = 𝑟 −2

point − source approximation
22

(2.13)

𝐺𝐿(𝑟, 𝜃) =

⎧
⎪

𝛽
𝑖𝑓 𝜃 ≠ 0°
𝐿𝑟𝑠𝑖𝑛𝜃
−1

⎨ 2 𝐿2
⎪�𝑟 − �4� 𝑖𝑓 𝜃 = 0°
⎩

Line source approximation

(2.14)

Where β (= 𝜃2 − 𝜃1 ) is the angle in radians subtended by the tips of the hypothetical line

source with respect to the calculation point. The geometry function used to calculate
radial dose and two dimensional anisotropy functions when deriving dose rates, should
use identical parameters including active length, L.

2.3.4 Radial Dose Function, gX(r)
The radial dose function,g X (r) accounts for dose fall off on the transverse plane

due to scattering and attenuation of photon fluence in a water medium. It is expressed
by the following equation
g X (r) =

Ḋ (r, θ0 ) GX (r0 , θ0 )
Ḋ (r0 , θ0 ) GX (r, θ0 )

(2.15)

The subscript “X” indicates whether a point source, “P”, or line source, “L”
approximation is used. In the present study, a line source approximation is used for all
Monte Carlo simulations.
A fifth order polynomial fit to the data is also useful as a means to efficiently
evaluate for any general position, r.
g X (r) = a0 + a1 r + a2 r 2 + a3 r 3 + a4 r 4 + a5 r 5
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(2.16)

Where a0 through a5 are constants. These constants should be determined and fit the
data for a treatment planning application over an acceptable range.

2.3.5 Two-Dimensional (2D) Anisotropy Function, F(r,θ)
The anisotropy function describes the variation of dose as a function of polar
angle with respect to the transverse plane. The 2D anisotropy function is small at
smaller polar angles and reaches unity at 90°.
𝐹(𝑟, 𝜃) =

Ḋ (r, θ) GL (r, θ0 )
Ḋ (r, θ0 ) GL (r, θ)

(2.17)

The large dose gradient near the radioactive sources makes it difficult to measure dose
rates at distances less than 0.5 cm. The Monte Carlo calculation method is more
reliable in estimating dose rates at shorter distances (<1 cm).14
The 2D anisotropy function decreases as (1) radial distance, r, decreases, (2) as
𝜃 approaches 0° or 180°, (3) as encapsulation thickness increases, (4) as photon
energy decreases. The same active length,L should be used to evaluate GL(r, θ) and to

extract g L (r), and F(r, θ) from dose distribution.

Some of the clinical treatment planning systems have adopted a one-dimensional

anisotropy approach. This ignores the orientation of the longitudinal axis of the source
and simplifies by approximating the complex two dimensional distributions. The 1D
anisotropy factor, ϕan (r) is expressed as

π
∫0 Ḋ (r, θ) sin(θ) dθ
ϕan (r) =
2Ḋ (r, θ0 )
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(2.18)

Therefore, this 1D anisotropy factor ϕan (r) is the ratio of dose rate at distance r,
averaged with respect to solid angle, to the dose rate on the transverse plane is at the
same distance. Equation (2.11) can be written as

GL (r, θ)
. g (r) . ϕan (r)
Ḋ (r) = SK . Λ .
GL (r0 , θ0 ) L
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(2.19)

CHAPTER 3 A MODERN MONTE CARLO INVESTIGATION OF THE TG-43
DOSIMETRY PARAMETERS FOR AN 125I SEED ALREADY HAVING AAPM
CONSENSUS DATA

3.1 Introduction
The AdvantageTM125I model IAI-125A brachytherapy seed (IsoAid LLC, Port
Richey, FL) has been available for clinical use since 2000. In 2002, Solberg et al. 12 and
Meigooni et al. 13 published the TG-43 14 dosimetry parameters for this seed using both
measurement and Monte Carlo (MC) calculation methods for radiation transport
simulations. The methodology to prepare American Association of Physicists in
Medicine (AAPM) consensus values for TG-43 dosimetry parameters are derived by
taking the combined results from MC calculations and TLD measurements.15 Given the
data in these two publications and the need for uniform clinical practice, the AAPM
approved posting of this seed on the joint AAPM/Radiological Physics Center (RPC)
Registry of Brachytherapy Sources on July 14, 2002.
In 2004, the AAPM published a task group report (TG-43U1)15 update to the
1995 TG-43 report14 to recommend improved dosimetry methods and dosimetric
characterization

of

low-energy

photon-emitting

brachytherapy

seeds.

A

2007

supplement AAPM report (TG-43U1S1) 16 included additional seeds such as the model
IAI-125A seed. AAPM consensus data used for the model IAI-125A seed was based on
the results from Solberg et al. and Meigooni et al. as these publications met the AAPM
dosimetric prerequisites. The line-source radial dose function gL(r) with an active length
of 0.3 cm, the 2D anisotropy function F(r, θ), and 1D anisotropy function φ(r) were
directly taken from Solberg et al. MC results, while the consensus value for the doserate constant Λ was taken as the average value from Solberg et al. and Meigooni et al.
results using MC and experimental methods.
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Over the past decade, the MC radiation transport codes used in preparation of
some AAPM consensus datasets have been revised. For example, Solberg et al. used
the MCNP4C code with photoelectric cross-section data from Berger and Hubbell, while
Meigooni et al. used the PTRAN code with the DLC 99 (data library code-99) photon
cross-section library. 17 In 2003, the MCNP5 code was released and included improved
photon interaction modeling and cross-section libraries. Moreover, 04p cross-section
library provided more data points between the energy range (10 keV to 80 keV) than
02p cross-section.50
In 2008, Taylor and Rogers calculated TG-43 parameters for the model IAI-125A
seed using the modified EGSnrc user-code called BrachyDose, 18 and obtained Λ values
4.0% and 5.9% lower than published by Solberg et al. and Meigooni et al., respectively.
Further, Taylor and Rogers obtained gL(r) values differing by greater than 10% from
Solberg et al. or Meigooni et al.
The model 6711

125

I seed (Oncura, Arlington Heights, IL), has a similar design to

the model IAI-125A seed. In 2010, Kennedy et al. 19 reported using the MCNP5 code for
simulating the model 6711 seed and reported a Λ value 6.2% lower than the 2007
AAPM TG-43U1S1 report consensus. 16 Due to the similarities of 6711 and IAI-125A we
would expect to see similar differences in obtaining dose rate constant (DRC) using
updated MCNP5 vs current consensus DRC data.
These inconsistencies in the dosimetry parameters in the literature and with the
AAPM consensus data are important, and prompted investigation on the potential
causes for these differences. The current study proposes a new reference dosimetry
dataset, compares this dataset to the published literature, and examines the sensitivity
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of radiation transport simulation results for the model IAI-125A seed to variations in MC
source modeling data.

3.2 Methods and Materials
Accurate MC simulations of brachytherapy seeds require knowledge of the
physical properties of the source. This includes the dimensions of all materials as well
as their compositions and densities. Some aspects are well understood through the
manufacturing process such as the length, thickness, and diameter of the source
capsule and internal components such as a radiopaque marker. However, other aspects
may not be well known such as the thickness and mass density of the radioactive
coating of the radiopaque marker.

3.2.1 Source Characteristics Model IAI-125A Seed
The model IAI-125A seed consists of a silver rod (right cylinder) contained within
a titanium capsule (4.54 g/cm3) with dimensions specified in Table 1. The capsule is
filled with argon gas at an assumed mass density of 1.662 mg/cm3. These source
characteristics were confirmed with the manufacturer and through external dimensional
measurements of radioactive seeds in a manner similar to Rivard et al. 20

All rod surfaces are uniformly coated with a silver iodide mixture. Following
review of the literature and discussion with the manufacturer, the coating thickness is
not well documented. Solberg et al. did not report the thickness, although private
communication indicated that a thickness of 0.5 µm was simulated. Meigooni et al.
assumed a thickness of 1 μm. Both thicknesses were used for creation of the
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consensus data recommended in the 2007 AAPM TG-43U1S1 report,16 but the
manufacturer recently informed us that 0.5 µm is more realistic. Therefore, the IAI-125A
seed was simulated using a variety of coating thicknesses (i.e., 0.1 µm, 0.5 µm, 1 µm,
and 2 µm) to investigate the influence of coating thickness variations on dosimetry
parameters. Two coating densities (4.93 g/cm3 and 6.003 g/cm3)13,21 were considered
based on variations used in the literature, where the latter value is considered more
representative of the manufactured product.

For benchmarking the simulations and quantitative comparisons due to its similar
design, TG-43 parameters for the model 6711
model IAI-125A

125

I seed were compared to those for the

125

I seed. The dimensions are also included in Table 3.1. Nominal

dimensions of the model IAI-125A seed and a schematic diagram depicting a crosssectional display as examined under the MC simulation conditions is shown in Figure
3.1.
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Table 3.1 Dimensional characteristics for the model IAI-125A and model 6711 125I seeds
(all dimensions are given in millimeters).
Parameter

model IAI-125A

model 6711

Ag rod length

3.00

2.80

Ag rod bevel at 45°

0.00

0.05

Ag rod diameter

0.50

0.50

Capsule outer length

4.50

4.55

Capsule inner length

3.70

3.75

Capsule outer diameter

0.80

0.80

Capsule inner diameter

0.70

0.66

Capsule endweld thickness

0.35

0.40

Figure 3.1 Schematic diagram of the model IAI-125A seed. The top image shows
nominal seed dimensions as specified by the manufacturer instructions for use. The
bottom image shows the proposed standard seed geometry from the MCNP5 visual
editor output.
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3.2.2 Monte Carlo Simulations
The MCNP5 radiation transport code was used for dosimetry simulations. 22 The
MCNP5 default photon cross-section library, MCPLIB04 (04p), was applied for
benchmarking. The older MCPLIB02 (02p) cross-section library was used for
comparison to the Solberg et al. and Meigooni et al. results. Based on the range of
secondary charged particles, simulations considered only photon transport. The

125

I

photon energy spectra in Table 2 were taken from Solberg et al., and the National
Nuclear Data Center (NNDC).12,23,24 The NNDC-based photon energy spectra were
taken as our proposed standard for comparison as it is more recent than that used by
Solberg et al., and the AAPM has recently recommended that NNDC spectra data be
reference data. 25
The seed was centrally positioned within a 20 cm radius water sphere having a
mass density of 0.998 g/cm3. 26 This volume was divided into a contiguous sampling
space bounded by spheres and conics as similar to the geometry used by Rivard for
another

125

I seed. 27 A 5 keV cutoff energy was used for dose-rate calculations using a

track-length estimator under the assumption of equivalence of absorbed dose to
collisional kerma.
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Table 3.2 125I disintegration photon energy spectra as used in the simulations. Note that
the provided NNDC-based spectrum23,24 excludes photons < 5 keV (i.e., 3.77 keV line),
and is normalized to unity for comparison with that of Solberg et al.12
Solberg et al.

NNDC-based

Energy

Intensity

Energy

Intensity

[keV]

[photons / history]

[keV]

[photons / history]

22.1

0.14

25.0

0.04

27.4

0.64

31.1

0.14

27.202

0.27730

27.472

0.51172

30.944

0.04723

30.995

0.09128

31.704

0.02628

35.5

0.04

35.4922

0.04619

27.4 (mean)

1.00

28.36 (mean)

1.00000

Twelve input simulation files were created in water and in vacuum to model the
IAI-125A seed with different coating thicknesses and mass densities, photon cross
section libraries, and photon spectra. These simulation conditions are listed in Table
3.3. Simulation condition 11 was proposed as an updated standard because it has the
most recent information on source design (coating thickness and density), cross-section
library, and photon energy spectrum. Results of TG-43 dosimetry parameters from
simulation condition 11 were compared to those obtained by Solberg et al., Meigooni et
al., Taylor and Rogers, and Kennedy et al. Further, results from all 12 simulation
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conditions were intercompared to determine the sensitivity of dosimetry results to each
variable.

Table 3.3 Simulation conditions used for MC modeling. Simulation condition 11 is
proposed for determination of a new reference dosimetry data. The DLC-99 crosssection library by Meigooni et al. and the XCOM cross-section library by Taylor and
Rogers may be considered equivalent to the 02p and 04p cross-section libraries
available within the MCNP code, respectively.
Coating

Coating

Photon

Endweld

energy

thickness

spectrum

[mm]

02p

S

0.24

Cross-section
Investigator

thickness

density
library

[µm]

[g/cm3]

Solberg et al.

0.5

Meigooni et al.

1.0

6.003

DLC-99

M

0.10

Taylor and Rogers

1.0

6.003

XCOM

TG-43U1

0.10

Kennedy et al.

1.75

6.20

04p

TG-43U1

0.40

Simulation condition 1

0.1

4.93

02p

S

0.35

Simulation condition 2

0.5

4.93

02p

S

0.35

Simulation condition 3

2.0

4.93

02p

S

0.35

Simulation condition 4

0.1

4.93

04p

S

0.35

Simulation condition 5

0.5

4.93

04p

S

0.35

Simulation condition 6

2.0

4.93

04p

S

0.35

Simulation condition 7

0.5

4.93

04p

N

0.35

Simulation condition 8

0.5

6.003

02p

N

0.35

Simulation condition 9

1.0

6.003

02p

N

0.35

Simulation condition 10

1.0

6.003

04p

N

0.35

10.48
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Simulation condition 11

0.5

6.003

04p

N

0.35

Simulation condition 12

0.5

6.003

04p

S

0.35

For spectrum choice, M= MIRD pamphlet 10, 28 N = NNDC-based,24 TG-43U1=Rivard et
al.15and S = Solberg et al.12

3.2.3 TG-43 Dosimetry Parameters
For MC simulations of air-kerma strength sK, the seed was positioned in vacuum
and the photon energy fluence was estimated ± 7.6° from the transverse plane to mimic
the sampling geometry of the Wide Angle Free Air Chamber (WAFAC) at the National
Institute of standards and Technology (NIST). 29 A thin vacuum shell (0.00002 mm) at
distance of 30 cm was created in order to score air kerma rate. In combination with the
dose rate in water on the transverse plane at r = 1 cm, Λ was derived according to the
approach described by Rivard.27 For all simulations in water, the phantom geometry and
sampling space was the same as that of Rivard.27Values for gL(r), F(r,θ), and φ(r) were
determined over the same range as that by Rivard.27 A total of 1010 and 109 particle
histories were used to assure minimal statistical uncertainties for vacuum and water
calculations, respectively. Specifically, the Type A uncertainties (k=1 coverage factor)
were 0.02% at r = 1 cm and 0.03% at r = 5 cm in water, and 0.02% at 30 cm in vacuum
for calculation of sK

3.2.4 Uncertainty Analysis
As recommended in the 2004 AAPM TG-43U1 report, a dosimetric uncertainty
analysis was performed to determine the uncertainties associated with each component
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of the MC simulation process. The uncertainties presented in Table 3.4 are based on
the similar methods as used by Rivard,27and following the 2012 AAPM TG-138 report
guidelines for specifying brachytherapy dosimetric uncertainties where a k=1 coverage
factor is provided. 30 The uncertainty components were derived as follows

(a) Due to the similar design with the model 6711
uncertainties for

d( 1, θ

0

),

d( 5, θ

0

) , and

125

I seed, the dosimetric

sK, were taken from Rivard.27 For the

dose-rate at 1 cm, this 0.3% value also matched that of Kennedy et al. These
uncertainties canceled out for derivation of Λ and gL(5) uncertainties.
(b) Many brachytherapy seeds exhibit dynamic internal components, see for
example Refs. 31 and 32. From the central position, the Ag rod in the model IAI125A seed can move laterally within the titanium capsule interior by a maximum
of 0.01 cm. Assuming a rectangular distribution for this motion and dose changes
attributed to changes in solid-angle, this results in uncertainties of 0.58%, 0.12%,
and 0.19% for

d( 1 cm, θ

0

),

d( 5 cm, θ

0

) , and

sK, respectively. These uncertainties

combined in quadrature for derivation of Λ and gL(5) uncertainties.
(c) Rivard et al.23 compared different

125

I photon energy spectra to determine their

dosimetric influence. Subsequently, a new data evaluation for the

125

I photon

energy spectrum following nuclear disintegration was performed by Katakura in
2011. 33 Upon comparison of this more recent data to the prior evaluation by
Katakura in 1999, 34 and with removal of the 3.77 keV photon from both spectra,
the mean photon energy changed from 28.3644 keV to 28.3676 keV,
respectively. Utilizing the 1999 and 2011 spectra in calculations of
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d( 1, θ

0

),

d( 5, θ

0

) , and

sK, the dosimetric uncertainties were 0.03%, 0.01%, and 0.04%,

respectively. While these uncertainties canceled out for the derivation of gL(5),
they combined in quadrature for the derivation of Λ for an uncertainty of 0.05%.

(d) The 2004 AAPM TG-43U1 report provides recommended compositions and
mass densities for water and air. Simplifying this as 0.1% uncertainty in the mass
density of the material, the estimated uncertainties (k=1) of

d( 1, θ

0

),

d( 5, θ

0

) , and

sK were 0.05%, 0.23%, and 0.002%, respectively. These uncertainties combined
in quadrature for the derivation of Λ and gL(5).
(e) Rivard et al.23 compared three different MC codes and found the dosimetric
influence on

d( 1, θ

0

),

d( 5, θ

0

) , and

sK for a point

125

I source to be about 0.1%

(k=1). This value was used herein for the model IAI-125A

125

I seed simulations.

These uncertainties canceled out for the derivation of Λ and gL(5) uncertainties.
(f) Using the PENELOPE MC code, Andreo et al. 35calculated the Type B
uncertainties for μen/ρ in water and air between 1 keV to 2 MeV. In water at 24.6
keV and 34.1 keV, Andreo et al. obtained standard (k=1) uncertainties of 0.82%
and 0.66%, respectively. At r = 1 cm and r = 5 cm, the mean photon energy in
water for the current study was about 27.30 keV and 27.17 keV, respectively,
corresponding to μen/ρ Type B uncertainties of 0.771% and 0.773%, respectively.
In air at 24.6 keV and 34.1 keV, Andreo et al. obtained standard (k=1)
uncertainties of 0.76% and 0.62%, respectively, which gave a μen/ρ Type B
uncertainty of 0.715% at the mean photon energy in vacuum at r = 30 cm. The
methods of Andreo et al. had statistical uncertainties of 0.07% (k=1). These
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uncertainties combined in quadrature for derivation of Λ, but canceled out for the
derivation of gL(5) uncertainties.
(g) The uncertainties in μ/ρ are estimated to be slightly less than the uncertainty in
μen/ρ. 36 Using a value of 0.6%, the resultant uncertainties on

d( 1, θ

0

),

d( 5, θ

0

),

and sK were 0.28%, 1.40%, and 0% (due to vacuum), respectively. These
uncertainties combined in quadrature for derivation of Λ and gL(5) uncertainties.
(h) The sampling voxels at 1 cm and 5 cm in water were 0.002 cm and 0.1 cm,
respectively, while the sampling voxel at 30 cm in vacuum was 0.02 μm thick.
This resulted in tally volume averaging uncertainties of 0.0001%, 0.01%, and <
0.0000001% for

d( 1, θ

0

),

d( 5, θ

0

) , and

sK, respectively. These uncertainties

combined in quadrature for derivation of Λ and gL(5) uncertainties.
(i) Photon histories totaling 109 and 1010 were used for simulations in water and
vacuum, respectively. This gave k=1 statistical uncertainties of 0.02%, 0.03% at
1 cm and 5 cm in water, respectively. For sK, the k=1 statistical uncertainty was
0.02%. These uncertainties combined in quadrature for the derivation of Λ and
gL(5) uncertainties.

Overall, the standard uncertainty for the TG-43 dosimetry parameters Λ and gL(5)
were 1.2% and 1.6%, respectively, and were dominated by the μen/ρ and μ/ρ
uncertainties. Some uncertainty components (such as the source capsule geometry and
the physics model used in the MC code) cancelled out for Λ and thus had lower overall
uncertainty than the uncertainty for the ratio of
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d( 1, θ ) /sK. This reduction in the overall
0

uncertainty was also true for the derivation of gL(5) where additional components that
canceled out included the source photon spectrum and μen/ρ.
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Table 3.4 Dosimetric uncertainty analysis of uncertainty components for MC simulations of the model
IAI-125A. The statistical (Type A) and non-statistical (Type B) uncertainty components are expressed
as percentages and are due to random and systematic effects, respectively.

d( 1, θ

0

d( 5, θ

Λ

sK

)

0

gL(5)

)

Uncertainty component
Type A

Type B

Type A

Type B

Type A

Type B

Type A

Type B

Type A

Type B

(%)

(%)

(%)

(%)

(%)

(%)

(%)

(%)

(%)

(%)

Source capsule

0.3

0.2

---

0.2

---

0.58

0.02

0.58

0.12

0.59

Source photon spectrum

0.03

0.04

0.05

0.01

---

Phantom composition

0.05

0.002

0.05

0.23

0.24

Physics of MC code

0.1

0.1

---

0.1

---

μen/ρ for dose calculation 0.07

0.771

μ/ρ for phantom

0.28

geometry
Dynamic internal
components

0.07

0.715
0

0.10

1.05
0.28

attenuation
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0.07

0.773
1.40

---

--1.43

Tally volume averaging

0.0001

Tally statistics

0.02

Quadrature sum

0.07

Total standard

1.06

0.00001

0.02
1.05

0.07

0.0001

0.03
0.75

0.10

0.75

1.24

uncertainty
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0.01

0.03
1.23

0.08

1.64

0.01

0.04
1.64

0.04

1.56

1.56

3.3 Results
3.3.1 sK
The sK values decreased with increasing coating thickness for both cross-section
libraries. Relative to the proposed standard value of a 0.5 μm coating thickness, the sK
values for the 0.1 μm and 2 μm coating thicknesses were 0.5% higher and 1.7% lower,
respectively. These differences would have no direct clinical impact, given that SK is
determined experimentally for individual seeds. Further these changes due to coating
thickness somewhat canceled with

d( 1, θ

0

) changes when deriving

Λ.

3.3.2 Λ
Table 3.5 lists Λ values using the twelve simulation conditions. In comparison to
the proposed standard value (0.922 ± 0.011 cGy.h-1.U-1), the Λvalues of Solberg et al.,
Meigooniet al., and Taylor and Rogers differed by +4.3% (0.962 cGy.h-1.U-1), +6.2%
(0.98 cGy.h-1.U-1), and +0.3% (0.925 cGy.h-1.U-1), respectively. Similarly the difference
in the proposed standard value and the similarly designed model 6711
0.2% based on Kennedy et al. (0.921 cGy.h-1.U-1).
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Table 3.5 Dose-rate constant Λ values published in the literature are compared to those
obtained using the twelve simulation conditions of the current study, and the proposed
standard value (simulation condition 11), along with relative values for the air-kerma
strength sK to the proposed standard value (simulation condition 11).
Λ
sK
Λ
Investigator
sK condition11
[cGy.h-1U-1]
Λcondition11
Solberg et al.

0.962

1.043

---

Meigooni et al.

0.98

1.062

---

Taylor and Rogers

0.925

1.003

---

Kennedy et al. (MC WAFAC)

0.921

0.998

---

Simulation condition 1

0.915

0.992

1.030

Simulation condition 2

0.916

0.993

1.025

Simulation condition 3

0.922

0.999

1.008

Simulation condition 4

0.886

0.960

1.025

Simulation condition 5

0.888

0.963

1.020

Simulation condition 6

0.894

0.969

1.003

Simulation condition 7

0.912

0.988

1.015

Simulation condition 8

0.951

1.031

1.004

Simulation condition 9

0.948

1.028

1.004

Simulation condition 10

0.921

0.998

0.999

Simulation condition 11

0.922

1.000

1.000

Simulation condition 12

0.896

0.971

1.009

The following observations were made upon altering the variables examined in the 12
simulation conditions
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a) Increasing coating thickness linearly increasedΛ. For ρ = 4.93 g/cm3, Λ increased
by 0.5% per μm increase in coating thickness.
b) Increasing coating density from ρ = 4.93 g/cm3 to ρ = 6.003 g/cm3 increased Λ by
about 1%.
c) Values for Λ were 3.1% higher for the 02p cross-section library than the 04p
cross-section library.
d) Values for Λ were 2.7% lower for the Solberg et al. spectrum than the NNDCbased spectrum, in agreement with the trend identified by Luxton and Jozsef, 37 in
which a 3.2% diminishment of Λwould be expected for a spectrum that is 0.964
keV lower than the NNDC-based spectrum.

3.3.3 gL(r)
Table 3.6 shows gL(r) results for the various simulation conditions where the
proposed standard is listed as simulation condition 11. These results were compared
with those published in the literature (Figure 3.2).
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Table 3.6 Radial dose function, gL(r), values from the twelve different simulations.
Results for simulation condition 11 are proposed as a new standard.
Coating thickness
[μm]

0.1

0.5

2

0.1

0.5

2

0.5

0.5

1

1

0.5

0.5

4.93

4.93

4.93

4.93

4.93

4.93

4.93 6.003 6.003 6.003 6.003 6.003

02p

02p

02p

04p

04p

04p

04p

02p

02p

04p

04p

04p

S

S

S

S

S

S

N

N

N

N

N

S

1

2

3

4

5

6

7

8

9

10

11

12

Coating density
3

[g/cm ]
Cross-section
library
Energy spectrum
r[cm] \Simulation
Condition

0.5

1.071 1.070 1.068 1.089 1.088 1.087 1.073 1.058 1.071 1.072 1.073 1.089

1.0

1.000 1.000 0.999 1.001 1.000 1.001 1.000 1.000 1.000 1.000 0.999 1.000

1.5

0.912 0.912 0.912 0.897 0.898 0.899 0.911 0.924 0.910 0.911 0.909 0.896

2.0

0.819 0.820 0.822 0.794 0.795 0.797 0.816 0.840 0.816 0.819 0.814 0.792

2.5

0.728 0.730 0.731 0.696 0.697 0.700 0.724 0.755 0.725 0.727 0.722 0.694

3.0

0.642 0.644 0.646 0.605 0.607 0.609 0.637 0.673 0.637 0.639 0.635 0.603

3.5

0.565 0.566 0.568 0.525 0.526 0.530 0.559 0.597 0.559 0.561 0.556 0.523

4.0

0.493 0.495 0.497 0.454 0.454 0.459 0.487 0.527 0.487 0.488 0.484 0.452

4.5

0.431 0.431 0.434 0.391 0.391 0.396 0.423 0.463 0.423 0.426 0.421 0.389

5.0

0.374 0.375 0.378 0.336 0.336 0.340 0.367 0.405 0.367 0.368 0.364 0.335
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5.5

0.324 0.326 0.328 0.288 0.289 0.291 0.316 0.354 0.317 0.318 0.314 0.287

6.0

0.282 0.282 0.286 0.247 0.248 0.250 0.272 0.309 0.273 0.274 0.271 0.245

6.5

0.244 0.245 0.247 0.211 0.212 0.214 0.235 0.268 0.236 0.237 0.233 0.210

7.0

0.212 0.212 0.214 0.181 0.182 0.183 0.202 0.234 0.202 0.204 0.200 0.180

7.5

0.182 0.183 0.185 0.155 0.155 0.157 0.173 0.203 0.174 0.175 0.172 0.153

8.0

0.158 0.158 0.160 0.133 0.133 0.134 0.149 0.176 0.149 0.150 0.148 0.132

8.5

0.136 0.137 0.138 0.113 0.114 0.115 0.127 0.153 0.128 0.129 0.127 0.112

9.0

0.118 0.118 0.119 0.0970 0.0973 0.0983 0.110 0.132 0.110 0.111 0.109 0.0964

9.5

0.102 0.102 0.103 0.0825 0.0830 0.0840 0.0933 0.114 0.0941 0.0947 0.0931 0.0821

10.0

0.0876 0.0876 0.0886 0.0704 0.0710 0.0714 0.0800 0.0986 0.0804 0.0805 0.0796 0.0701

n.b., For the choice of spectrum, N = NNDC-based,24 and S = Solberg et al.12
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Figure 42 Ratio of gL(r) from published literature to the current study using simulation
condition 11. Solid curves are used for the data points from Taylor and Rogers and for
Kennedy et al. to guide the eye given their proximity to unity.

From results of the 12 different simulation conditions, changing coating thickness
had a small effect on gL(r). Changes in gL(r) correlated approximately linearly with
coating thickness changes and increased as r increased. For ρ = 4.93 g/cm3, gL(r > 5)
increased by 0.8% per μm increase in coating thickness. Changing coating density also
had a small affect such that an increase in ρ from 4.93 g/cm3 to 6.003 g/cm3 caused gL(r
> 5) to increase by 1%.
The 02p cross-section library consistently produced gL(r) results higher than the
04p cross-section library, with an approximately linearly relationship of +2.74%/cm with
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an R2 fit of 0.997. Thus, gL(10) using 02p was 25% larger than the value using the 04p
cross-section library.
Use of the spectrum by Solberg et al. in comparison to the NNDC-based
spectrum of simulation condition 11 influenced gL(r) in a non-linear manner by +1.5%, –
2.6%, –8.2%, and –11.6% at r = 0.5, 2, 5, and 10 cm, respectively.

3.3.4 F(r, θ)
Table 3.7 presents the F(r,θ) data for the model IAI I-125 seed from the MC
simulation condition 11. The values increase gradually towards unity as θ approaches
90°.

Table 3.7 F(r,θ) and φ(r) values for the IsoAid model IAI I-125 125I seed determined
using MC methods for simulation condition 11.
θ\r

0.5

1.0

1.5

2.0

2.5

3.0

4.0

5.0

7.0

10.0

0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85

0.21
0.39
0.45
0.58
0.69
0.78
0.85
0.91
0.95
0.98
1.00
1.01
1.03
1.03
1.03
0.98
0.99
0.99

0.28
0.48
0.53
0.64
0.72
0.79
0.85
0.90
0.94
0.97
0.99
1.01
1.02
1.03
1.03
1.03
1.03
0.99

0.35
0.53
0.58
0.67
0.75
0.81
0.86
0.90
0.94
0.96
0.99
1.00
1.01
1.02
1.03
1.03
1.03
1.00

0.42
0.56
0.62
0.70
0.77
0.82
0.86
0.90
0.94
0.96
0.98
1.00
1.01
1.02
1.03
1.03
1.03
1.02

0.44
0.59
0.64
0.71
0.78
0.83
0.87
0.91
0.94
0.96
0.98
1.00
1.01
1.02
1.02
1.03
1.03
1.02

0.48
0.61
0.66
0.73
0.79
0.84
0.88
0.91
0.94
0.96
0.98
1.00
1.01
1.02
1.02
1.03
1.03
1.02

0.50
0.64
0.69
0.75
0.81
0.85
0.88
0.91
0.94
0.96
0.98
0.99
1.00
1.01
1.01
1.02
1.02
1.02

0.55
0.66
0.71
0.76
0.81
0.85
0.88
0.91
0.94
0.96
0.98
0.99
1.00
1.01
1.01
1.01
1.01
1.01

0.62
0.69
0.73
0.78
0.83
0.86
0.89
0.92
0.94
0.95
0.97
0.98
1.00
1.00
1.01
1.01
1.01
1.02

0.68
0.73
0.77
0.80
0.85
0.88
0.90
0.92
0.94
0.96
0.98
0.99
1.00
1.00
1.01
1.01
1.02
1.01
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90
φ(r)

1.00
0.98

1.00
0.97

1.00
0.96

1.00
0.97

1.00
0.97

1.00
0.97

1.00
0.96

1.00
0.96

1.00
0.96

1.00
0.97

Changes in F(r,θ) values as a function of the simulation condition variables were
smaller than the observed differences between the current study (i.e., simulation
condition 11) and the results of Solberg et al. and Meigooni et al. The following
observations were made upon altering the variables examined in the 12 simulation
conditions
a) coating thickness changes of 0.4 μm, 1.5 μm, and 1.9 μm decreased F(r,θ) by >
2% at θ< 7°, θ< 14°, and θ< 17°, respectively, using the 02p library. F(r,θ)
increased by > 2% at θ< 8°, θ< 22°, and θ< 23°, respectively,
b) changing coating density from ρ = 4.93 g/cm3 to ρ = 6.003 g/cm3 decreased
F(r,θ) by > 2% for about θ< 12°,
c) changing cross-section library from 02p to 04p increased F(r,θ) by > 2% for θ<
3°, and
d) changing photon spectrum from Solberg et al. to the NNDC-based spectrum
increased F(r,θ) by > 2% for θ< 24°.
These observations were made for 0.5 <r< 10 cm, where F(r,θ) differences generally
increased as both r and θ decreased. The observed order of simulation condition
variables from most to least important for influencing F(r,θ) were spectrum, coating
thickness, coating density, and cross-section library.
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3.4 Discussion

3.4.1 Λ
Four different photon energy spectra were used for the computations examined
in the current study. Compared to the 2011 evaluation by Katakura the mean photon
spectra used by Solberg et al., Meigooni et al., Taylor and Rogers as well as Kennedy
et al. and that of the current study were all lower by 0.964 keV, 0.039 keV, 0.001 keV,
and 0.003 keV respectively. From the sensitivity of Λ from sec. 3.2, only the Solberg et
al. study would be affected by more than 0.1% due to spectral choice.

3.4.2 gL(r)
From Fig. 2, differences between results of the current study (simulation
condition 11) and those of Solberg et al. were less than 5% for 0.5 <r< 5 cm. For larger
r, disparities up to 30% were observed and mainly attributed to differences in the crosssection libraries and photon energy spectra. For a similar comparison of results for the
current study and those of Meigooni et al., 5% agreement was observed only for r< 2.5
cm with the Meigooni et al. value of gL(2.5) = 0.750 being 3.8% larger than those from
simulation condition 11. From sec. 3.3.C, a 4.1% increase would be expected solely
based on differences in cross-section libraries, which is in good agreement with the
observed difference. Further, the Meigooni et al. value of gL(6.5) = 0.269 was 15.3%
larger than those from simulation condition 11. Applying the cross-section library linear
correlation correction of +2.74%/cm from sec. 3.3.C, an increase of 15.1% would be
expected, which was similar to the observed 15.3% difference.
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Comparisons over the entire range of 0.5 <r< 10 cm from simulation condition 11
to Taylor and Rogers and to Kennedy et al. were in agreement within 2% and 0.5%,
respectively, justifying the rigor of the current study and the assumed simulation
conditions.
3.4.3 F(r,θ)
Upon comparing F(r,θ) values of Solberg et al., Meigooni et al., Taylor and
Rogers, and Kennedy et al. to the proposed standard of MC simulation condition 11 as
shown in Figure 3.3, substantial differences were observed at θ< 20°. At F(1 cm, 10°),
Meigooni et al. was 37% larger than the current study. At F(3 cm, 10°), results from the
MC studies of Meigooni et al., Taylor and Rogers, and Kennedy et al. differed from the
current study by more than 5%. This discrepancy was thought to be due to differences
in the simulated end-weld thickness (see Table 3.3). These differences diminished as
radial distance increased as did the proportion of radiation scatter to total dose.
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Figure 53 (a) Ratios of F(r,θ) values at 1 cm to current study (simulation condition 11).
The results showed that 1-2%, 37%, 5% and 18% with Solberg et al., Meigooni et al.,
Taylor and Rogers, and Kennedy et al. at 10˚ respectively.
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Figure 6(b) Ratios of F(r,θ) values at 3 cm to current study (simulation condition 11).
The results showed that 3%, 6%, 7% and 13% with Solberg et al., Meigooni et al.,
Taylor and Rogers, and Kennedy et al. 10˚ respectively. The anisotropy effect was
higher at smaller angle at smaller distance.

Taking from modern data for the photon interaction cross-section libraries and
photon energy spectrum, the remaining simulation condition variables influencing F(r,θ)
are based on the design of the model IAI-125A seed. While the design parameters in
MC simulation condition 11 are thought to be most representative of the current
manufacturing process, variability in the dose distribution and subsequently the
resultant TG-43 dosimetry parameters such as F(r,θ) upon altering coating thickness
and coating density have been gleaned. The influence of these design variables on
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F(r,θ) was largest when close to the source long-axis. However, like the Λ and gL(r)
results, this influence diminished to 1% when F(r,θ) was replaced with φ(r) upon using
the 1D dose calculation formalism.
3.4.4 Consensus Data for Uniform Clinical Use
The AAPM consensus data for the model IAI-125A 125I seed are based on results
from Solberg et al. and Meigooni et al. However, examination of the simulation
parameters such as varying

125

I coating thickness, coating mass density, photon

interaction cross-section library, and photon emission spectrum indicated that significant
variations in calculated dosimetry parameters may arise if modern values are not
utilized. However, it is noted that simply running a new version of a transport code and
using the most recent cross section libraries does not necessarily ensure improved
results. 38In the 2004 AAPM TG-43U1 report, consensus data were updated from the
1995 TG-43 report for the model 6711

125

I seed and model 200

103

Pd seed, but there

have been no further updates of consensus data for other seeds given the recent
increase of investigations on the topic of brachytherapy seed dosimetry parameters.
Like the regular evaluations of nuclear data over time in other fields of physics,24 it
seems that the AAPM or other professional societies should establish a practice to
regularly reevaluate consensus data given subsequent publication of results for a given
brachytherapy seed.
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3.5 Conclusions
Radiation transport simulations were performed using the MCNP5 code in a
standardized manner for the IsoAid model IAI-125A seed for determination of the TG-43
dosimetry parameters. Several MC radiation transport codes are available for
calculation of the TG-43 dosimetry parameters for brachytherapy seeds. The physics
models in these codes and their related cross-section libraries have been updated and
improved since the 2002 publications of Solberg et al. and Meigooni et al., as well as
publication of the 2007 AAPM TG-43U1S1 report. Results using modern data indicated
statistically significant differences in these dosimetry parameters in comparison to data
recommended in the TG-43U1S1 report. These differences were explained by
conducting a sensitivity study of results to simulation parameters such as varying

125

I

coating thickness, coating mass density, photon interaction cross-section library, and
photon emission spectrum. While the results of Solberg et al. and Meigooni et al. were
used to obtain the consensus data in the TG-43U1S1 report, some simulation
parameters in these two studies appear outdated. Results from Taylor and Rogers and
those in the current study reflect modern assessments of the TG-43 dosimetry
parameters. These results may be considered by the AAPM for reevaluating the
consensus data for this seed, and for establishing a process of regular evaluations for
other seeds in which the consensus data are based on methods that are no longer
state-of-the-art.
Copyright © Prakash Aryal 2014
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CHAPTER 4 INDEPENDENT DOSIMETRIC ASSESSMENT OF THE MODEL EP917
EPISCLERAL BRACHYTHERAPY PLAQUE

4.1 Introduction
The most common cancer of the eye is uveal melanoma, and eye plaque
brachytherapy is the treatment of choice for small lesions. 39,40 Brachytherapy has been
used for treatment of ocular lesions since the 1930s, 41 and the Collaborative Ocular
Melanoma Study (COMS) plaques have been commonly used since the 1980s for eye
plaque brachytherapy. 42 The randomized, multi-institutional Phase-III COMS trial
demonstrated no differences in survival between enucleation and brachytherapy for
small eye lesions. 43 These COMS-style plaques are circular, 2.8 mm thick, and
accommodate

low-dose

rate

brachytherapy

seeds

containing

125

I,

103

Pd,

or

131

Cs. 44However, treatments can be problematic with 2.8 mm thick COMS plaques and

for elongated tumors. 45 Therefore, other plaque designs have been proposed. 46,47
The model EP917 brachytherapy eye plaques (IsoAid, LLC, Port Richey, FL)
were initially named University of Southern California (USC #9) plaques, developed by
Eye Physics, LLC (Los Alamitos, CA), and were designed to overcome the
aforementioned deficiencies of the COMS plaques by collimating radiation from each
brachytherapy seed with a slot machined into a gold-alloy backing. The slot designed
proposed by Astrahan et al.45 is depicted in Fig. 4.1a. Examination of the three EP917
plaques in our clinic indicated that that the slots were different than the design by
Astrahan et al. and also different than the design in the Plaque Simulator (PS) treatment
planning software (Eye Physics, LLC, Los Alamitos, CA). To resolve these
discrepancies, an investigation was performed to accurately measure the eye plaque
slots and overall design, and to determine the dosimetric influence of eye plaque design
variations using Monte Carlo (MC) methods for radiation transport simulations. This type
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of study, to independently assess the reported design of the Eye Physics plaques, has
not been performed previously to our knowledge, and demonstrates the need for a
robust acceptance testing procedure.

Figure 4.1 Various slot designs are possible with eye plaque brachytherapy. (a) the slot
design proposed by Astrahan et al. as adapted from their Fig. 2, (b) simulated geometry
of the Astrahan et al. slot (AS) with slot length and width of 6.00 mm and 2.00 mm,
respectively, with a slot depth of 1.40 mm, (c) simulated geometry of the Plaque
Simulator version 5.7.6 slot (576S) with slot length and width of 4.79 mm and 1.18 mm,
respectively, with a slot depth of 0.81 mm, and (d) simulated geometry of the measured
slot (MS) with length, width, and depth of 5.40 mm, 1.20 mm, and 0.46 mm.
respectively. The left and right sides show longitudinal and transverse planes,
respectively, through the slots and seeds. All Monte Carlo simulations were for the
model IAI-125A 125I seed.

Marwaha et al. 48 showed that the dose to macula, optic disc, and opposite retina
structures was reduced by 13.2%, 5.4%, and 0.6% respectively, using the model EP917
plaque in comparison to COMS plaques. However, the slot dimension including the
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depth of such plaques was not mentioned. Zimmermann et al. 49 compared doses
calculated using PS v.5.7.4 and MC methods for the model EP917 plaque loaded with
the model IAI-125I

125

I seed (IsoAid, LLC, Port Richey, FL) loading only the central slot,

i.e., slot #1 in v.5.7.6 in PS. PS doses differed from the MC results by 32.4% and 12.5%
at 1 mm and 2 mm from scleral surface, but matched within 5% for depths ranging from
3 mm to 12 mm. However, this abstract did not examine a fully-loaded plaque or provide
dimensional information on the planned or simulated slots. Consequently, we
hypothesized that plaque design differences would substantially influence dose
distributions for episcleral brachytherapy.
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4.2 Methods and Materials

4.2.1 Monte Carlo methods
Version 1.40 of the MCNP5 MC radiation transport code 50 was used for
simulation of 2D and 3D dose distributions. The collision kerma was approximated as
absorbed dose for low energy photons, and electron transport was ignored. The default
MCNP v.1.40 photon cross-section library (MCPLIB04) was used for all simulations, and
the *F4 track length estimator was used with tally modifiers based on mass-energy
absorption coefficients from the National Institute of Standards and Technology. 51 The
most recent

125

I photon energy spectrum from the National Nuclear Data Center52was

used in these simulations, including the 3.77 keV photon, which may contribute to dose
within 1 mm of the source in water or tissue. A total of 1010 photon histories were
simulated for each slot and plaque design to minimize the statistical uncertainties. In
general,

the

MC

simulation

methods

performed

by

Rivard

et

al.

were

followed. 53However, the medium surrounding the single-slot geometries and the eye
plaques adjacent to the ocular globe were surrounded with a 10 cm diameter sphere of
liquid water (0.998 g/cm3). All materials (other than the

125

I seeds and the gold alloy)

were assumed to be composed of water, and all reported dose values are to water in
water.
4.2.2 Slot Designs

To glean insight into the potential reasons for dosimetric differences in plaques
having differing slot designs, the geometry of a single slot was considered. The primary
comparison was between the manufacturer-reported slot dimensions and the measured
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slot dimensions. Astrahan et al. published a slot length, width, and depth values of 6.00,
2.00 mm, and 1.40 mm, respectively (Fig. 4.1a).45 However, values for these
dimensions included in the most recent version of the PS software (version 5.7.6)
available to us as of this writing were smaller, i.e., 4.79, 1.18, and 0.81 mm,
respectively. Consequently, slot dimensions values from the PS software were taken as
the manufacturer-reported slot dimensions for simulations (Fig. 4.1b) and are referred to
as 576S.
Measurements were performed to independently evaluate this and resolve the
dimensional differences between this publication and the values provided in the PS
software. Using a ruler calipers, and photomicroscopy, 54 the slot was determined to
have a circular cross section and to have hemispherical ends (Fig. 4.1c) instead of the
isosceles trapezoidal cross-section described by Astrahan et al. or utilized in the PS
software. This fits with our understanding of the manufacturing process for our plaques,
in which a rounded bit was used with a dental tool for slot fabrication. Fig.1B in
Marwaha et al.48 and in Berry et al. 55 also depict slots having rounded ends. For three
model EP917 plaques, the measured lengths and widths for the slots were 5.4 mm and
1.2 mm, respectively, with a variation of about 0.1 mm (k=1) in both dimensions. The
measured depth (at the midpoint of the seed) for 51 slots (three plaques) ranged from
0.16 mm to 0.73 mm, with an average depth of 0.46±0.16 mm (k=1). Depth
measurement precision was estimated as 0.04 mm (k=1). There was no observed
correlation in slot depth as a function of distance from the plaque central axis (CAX) or
other physical aspects. Measurements at another institution having the same plaque
model were in agreement with the slot depths determined in the current study. 56
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Due to the plaque curvature to conform to the eye, slot depths increased towards
the slot ends since the slot bottoms were not curved to accommodate the seeds (Fig.
2a). However, for the study of single-slot dosimetry, a single value was chosen for
characterizing the slot depth. This measured slot design (referred to as MS) was
compared through simulations of the slot geometries by Astrahan et al. (AS) and the
576S design.
Secondary comparisons of variants of the measured slot design evaluated the
sensitivity of the dose distribution to design variations and assumptions inherent to the
simulations. These variations include plaque mass density ρ and plaque composition;
slot length, width, and depth; seed positioning; and Ag-marker rod positioning. The
nomenclature of nMS represents narrow slots (5.00, 0.80, and 0.46 mm long, wide, and
deep, respectively) and dMS represents narrow and deep slots (5.00, 0.80, and 0.97
mm long, wide, and deep, respectively). These nMS and dMS slots were theoretically
designed and simulated to examine the sensitivity of dose distribution to the slot design.
Quantitative tolerances for applicator dimensions were not provided in the AAPM
TG-40 report on radiation oncology quality assurance, 57 the AAPM TG-56 report
establishing a brachytherapy code of practice for medical physics, 58 or the ESTRO
Booklet 8 on European brachytherapy quality assurance standards. 59However, the
AAPM TG-40 report (Table XI) recommended that brachytherapy applicators be
inspected upon initial use and yearly, and that brachytherapy dose should be delivered
within 5% limits. Therefore, a dose change of 5% was used to categorize a change in
slot design as being important.
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The plaque manufacturer indicates that the plaque is composed of 18K gold.
However, the ρ and composition of 18K gold is not standardized. 60,61,62, A value of

ρ=15.58 g/cm3 has been cited,60 but this is dependent on alloy composition.
Characteristic x ray production is dependent on the plaque composition, and low-energy
photons emitted from low dose-rate brachytherapy seeds such as

125

I,

103

Pd, and

131

Cs

induce x ray production in the elements comprising the alloy. These characteristic x rays
emanate from Au, Ag, and Cu with energies of 11-13 keV (L-edge), 22-25 keV (K-edge),
and 8-9 keV (K-edge), 63,64 respectively, and enhance the dose near the seed due to
fluorescent photons and the photoelectric effect. To evaluate the dosimetric influence of
altering the gold alloy ρ and composition, simulations of the MS slot design were
performed for ρ=15.58 g/cm3 and an extreme case of ρ=19.3 g/cm3, and for proportions
by mass of Au:Ag:Cu from 75%15%10% and 75%2.75%22.25%, respectively.61,62These
compositions are referred to as Ag=15% and Ag=2.755%, respectively. Dose ratios of
these combinations were used to evaluate the importance of each material property,
i.e., ρ and composition, for the MS slot design. An additional simulation was performed
for the Astrahan et al. slot design to evaluate the dosimetric importance of changing the
18K gold alloy mass density and composition from ρ=15.58 g/cm3 to ρ=19.3 g/cm3 and
Ag=15% to Ag=2.755%, referred to as alloyAS in the current study.
The model IAI-125A 125I seed was positioned in every slot design evaluated. 65 To
determine the sensitivity of dose to position of this seed within a slot, the entire seed
was offset laterally within the slot by 0.0994 mm, vertically out of the slot by 0.0994 mm,
and/or longitudinally along the slot by 0.3495 mm. These shifts (Table 4.1)
corresponded approximately to the maximum possible shifts without capsule collision
61

with the slot or penetration into the ocular globe. Further, the Ag-marker rod within the
125

I seed capsule was also shifted (Table 4.1) maximally to account for dynamic internal

components. 66 The rod was offset laterally within the capsule by 0.0994 mm, vertically
towards the ocular globe by 0.0994 mm, and/or longitudinally towards the capsule
endweld by 0.3495 mm. These rod shifts were the maximum possible within the
capsule. Subsequently, the entire seed was shifted by the same amount as the rod.
This was done so that dosimetric differences due to shifting of the Ag rod or the
surrounding Ti capsule could be separately identified.
For all slots designs evaluated, dose was estimated on three orthogonal planes.
The in-plane resolution was (0.01 cm)2 with an overall extent of (2.51 cm)

2

for a

251×251 array on the xz, yz, and xy planes (Fig. 4.1b). The planar thickness was
chosen as 0.01, 0.05, and 0.05 cm, respectively, to minimize in-plane dose gradients.
Dose along the slot CAX at 1, 2, 5, and 10 mm from the origin along the z axis was also
evaluated. The coordinate system origin for the single-slot study was at the center of the
125

I seed.
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Table 4.1 It is possible to shift the seed position within the slot, and the Ag rod within the
IAI-125A 125I seed to move within the Ti capsule. Monte Carlo simulations were
performed with shifts based on the measured dimensions of the reference slot design
(MS). Variants of seed offsets and rod offsets were examined to evaluate their
dosimetric influence. Values for all dimensions are in millimeters.
Offset

Seed xz

Seed y

Seed z

Seed yz

Rod x

Rod y

Rod z

Rod yz

Seed x

0.0994

0

0

0

0

0

0

0

Seed y

0

0.3495

0

0.3495

0

0

0

0

Seed z

0.0994

0

0.0994

0.0994

0

0

0

0

Rod x

0

0

0

0

0.0994

0

0

0

Rod y

0

0

0

0

0

0.3495

0

0.3495

Rod z

0

0

0

0

0

0

0.0994

0.0994

4.2.3 Plaque designs
From the dosimetric study of the slots, five slot designs were included for
evaluation of the model EP917 plaque having 17 slots in total. This included the
measured slot (MP) and variants to explore dosimetric sensitivity to slot design
variations (Table 4.2) with the last letter “P” indicating plaques where “S” was used in
Sec. 2.B for single slot simulation. While the slot shape from the PS software was
accurately simulated for the single-slot study, the exact slot shape used in PS to
perform treatment planning for the model EP917 plaque could not be simulated
because of overlap at the slot corners. Consequently, slot dimensions from the PS
software were approximated (576P) and are indicated in (Table 4.2). A narrow version
of the reference measured plaque, i.e., nMP, was also examined. The original slot
design of Astrahan et al. was not included in the dosimetric evaluation of plaques
because the slots would substantially overlap given the measured slot positions. Also, in
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contrast to the single-slot simulations where the measured slot depth (at the midpoint of
the slot length) was consistent over the entire length of the slot due to the rectangular
geometry, the slot depth varied for simulations with the curved plaques and the slot
design from Astrahan et al. could not physically fit within the 1.0 mm thick plaque.
Therefore, the dosimetric influence of changing the slot length, width, and depth was
examined in the dMP plaque design (Table 4.2) where the seed position was kept at the
bottom of the slot and subsequently moved 0.51 mm away from the ocular globe due to
the deeper slot depth.
Table 4.2 Several plaque designs were examined using Monte Carlo methods. The slot
dimensions are given in millimeters.
Plaque

Description

Length

Width

Depth

576P

Plaque Simulator v.5.7.6 approximation

4.50

1.06

0.60

MP

measured slot for standard plaque

5.40

1.20

0.46

sMP

shift rod 0.0994 mm toward globe

5.40

1.20

0.46

nMP

narrow slot length and width

5.00

0.80

0.46

5.00

0.80

0.97

narrow slot length and width, deep slot,
dMP
and 0.51 mm seed shift away from globe
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Figure 4.2 Slot positions for the model EP917 eye plaque were based on
measurements using photomicroscopy. The plaque (a) is loaded with three dummy 125I
seeds (model IAI-125A), and the reference Monte Carlo simulation model showing
simulated positions of the 125I-laden cylindrical Ag rods within the Ti capsules (b). The Zaxis direction points out of the page. The ruler indicates units in centimeters with
increments in millimeters.

In versions of the PS software used at the start of this investigation (v.5.3.6 and
v.5.3.7), 13 of the 17 slots overlapped and were physically implausible. As the plaques
did not exhibit the overlap as indicated by the PS software and the slots were not
symmetric about the YZ plane (Fig. 4.2a), measurements were performed to
independently obtain the coordinates and orientations for the 17 slots. High-resolution
images (3672×4866 pixels) of the model EP917 plaques were taken with a digital
camera (model DSC-HX20V, Sony Corp., Tokyo, Japan). The camera settings and
position (i.e., 20 cm) relative to the plaque were such that image divergence was
minimal.
Camera image accuracy was verified by examining a fixed grid and quantifying
any image distortion. The barrel effect due to von Seidel aberrations was measured
over the central region of the image where the plaque was located. 67,68 Image distortion
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was about 0.2% at the corners of the plaque image, which corresponded to an error of
about 1 pixel (about 0.012 mm). Thus, the plaque images were considered to be
accurate and the assignment of spatial position in terms of pixels was valid. This finding
was further validated by examining the ruler (positioned beyond the plaque) where
differences between the millimeter scales across the field-of-view (7 mm lateral and ±10
mm longitudinally) were also no more than 1 pixel. Consequently, slot position
measured on the image was used for the simulated slot position in the plaque (Fig.
4.2b). Orientation of the slots out of the image plane was accounted for using
trigonometric calculations based on the plaque curvature about the ocular globe. The
slot coordinates from the PS software (version 5.7.6) and the measured results are
given in Table 4.3. The average distance between PS and measured slot centers was
0.07 cm (range 0.02-0.10 cm). The main difference was our assignment of the Y axis
along slots #7 and #14 (Table 4.3), whereas PS v.5.7.6 placed slot #1 at Y=0. When
accounting for this 0.07 cm offset in the Y direction, the average distance was then 0.04
cm (range 0.01-0.06 cm).
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Table 4.3 Slot center coordinates from the Plaque Simulator software (version 5.7.6)
and measured using photomicroscopy for the model EP917 plaque. The coordinate
system is indicated in Fig. 4.2a and Fig. 4.3. Values for all dimensions are in
centimeters.
PS v576 coordinates
Slot

X

Y

1

0.000

0.000

2

0.000

3

Measured coordinates
Z

X

Y

Z

-0.160

0.000

0.050

-0.141

0.494

-0.062

0.000

0.578

-0.004

0.009

-0.494

-0.062

0.000

-0.487

-0.045

4

-0.239

0.513

-0.029

-0.231

0.576

0.020

5

-0.407

0.421

-0.019

-0.399

0.476

0.020

6

-0.399

0.161

-0.086

-0.367

0.231

-0.066

7

-0.395

-0.055

-0.097

-0.367

0.000

-0.088

8

-0.386

-0.324

-0.057

-0.367

-0.231

-0.066

9

-0.342

-0.547

0.013

-0.367

-0.463

0.003

10

-0.331

-0.779

0.156

-0.359

-0.696

0.128

11

0.371

-0.761

0.156

0.359

-0.696

0.128

12

0.361

-0.535

0.013

0.367

-0.463

0.003

13

0.370

-0.311

-0.066

0.367

-0.231

-0.066

14

0.373

-0.059

-0.104

0.367

0.000

-0.088

15

0.364

0.162

-0.097

0.367

0.231

-0.066

16

0.414

0.414

-0.019

0.399

0.476

0.020

17

0.239

0.513

-0.029

0.231

0.576

0.020

The coordinate system origin for the plaque simulations differed from the singleslot study. The z=0 position for the slot was centered in the seed and the Z=0 position
for the plaques was positioned along the plaque CAX at the inner sclera (Fig. 3). The
plaque was simulated as being symmetric about the YZ plane at X=0. This assumption
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was considered reasonable based on the observed manufacturing tolerances when
comparing the three model EP917 plaques. Except for the dMP design where seeds
were 0.51 mm from the outer sclera, the seeds within the plaque were simulated as
being in contact with an eye. The plaque and ocular globe were centered in a 5 cm
radius water sphere to provide photon scattering conditions to approximate an infinitely
large phantom. A tumor was simulated (Fig. 4.3) with a basal diameter of 11 mm and an
apical height of 5 mm, 69 and aligned with its CAX oriented along the Z axis with the
tumor apex positioned at Z=0.5 cm. To simulate human anatomy as a means of
modeling dose-associated toxicity, the inner sclera (to approximate retinal dose) was
defined at an ocular radius of 1.13 cm, and the outer sclera was defined at an ocular
radius of 1.23 cm.

Figure 4.3 Monte Carlo dose calculation environment depicting a simulated model
EP917 brachytherapy eye plaque (MP) loaded with model IAI-125A 125I seeds centrally
positioned within each slot. As would be performed for a clinical procedure, the
simulated plaque is in contact with an eye having a 1 mm thick sclera. Also shown is a
simulated tumor with a basal diameter of 11 mm and an apical height of 5 mm. The
coordinate system origin is located on the plaque CAX at the inner sclera (Z=0), with the
Y axis pointing out of the page.
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As was performed for the slot design assessment, dose was estimated on three
orthogonal planes for the plaque study. Further, dose volume histograms (DVHs) were
created for the tumor, inner sclera, and outer sclera. These volumes were radially
segmented about the Z axis with 0.01 cm resolution. The tumor volume was further
subdivided along the Z axis with 0.02 cm resolution, for a total of 536 volume elements.
Dose in the scleral regions was obtained for Z<0.5 cm with 0.1 µm thick voxels to
minimize dose volume averaging. There were 94 and 106 volume elements for the inner
sclera and outer sclera, respectively. These volume elements were created where the
tumor was introduced and the EP917 plaque would be positioned. The DVH results
were further analyzed through consideration of the high dose region using D10, the dose
delivered to at least 10% of the volume for the tumor, inner sclera, and outer sclera.
The prescription at our institution for a 96 h implant has been a dose of 85 Gy to
the tumor apex. Using the PS software with the revised dosimetry data for the model
IAI-125A

125

I seed,65 this required 3.279 U per seed. To provide direct comparisons

between the PS software results and the MC results, raw values for the simulated dose
were corrected according to the methods of Melhus and Rivard. 70 For the model IAI125I

125

I seed, the conversion factor from native MCNP output (i.e., MeV/g/s.p.) to Gy

was determined to be 222,452±222 (k=1). Consequently, the MC results were reported
in terms of Gy for the same prescriptive criterion, 3.279 U/seed for a 96 h implant. Due
to the substantial slot-design differences between the dMP and MP plaques, doses from
the dMP plaque were normalized to match the MP dose at 0.5 cm on the CAX for
comparison with the other simulated plaques. The normalized dMP plaque results are
referred to as dMP’.
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4.3. Results
4.3.1 Slot Design
4.3.1.1. Mass Density and Plaque Composition
Using the notation defined in Sec. 2.A for gold-alloy ρ and composition, the dose
ratio for the standard MS slot design with Dρ=19.3/Dρ=15.58 was 0.999 at 1 mm from the
source, equilibrating to about 0.998 beyond 3 mm. The dose ratio for the standard MS
slot design with DAg=0.15/DAg=0.02755 was 0.993 at 1 mm from the source, equilibrating to
about 0.985 at larger distances. Statistical uncertainties (k=1) were <0.1%. When both
mass density and gold-alloy composition were altered for the MS slot design, there were
no statistically-significant differences with the conditions where only composition was
altered. The dosimetric influence of changing gold-alloy ρ or composition was largest
along the CAX of the slot aperture. At locations outside the slot aperture where radiation
scatter dominated, changing gold-alloy ρ or composition produced even smaller effects.
The dose ratio (alloyAS/AS) for the slot design by Astrahan et al. was 0.985 at 1
mm from the source, equilibrating to about 0.976 beyond 3 mm. Given the slot design
by Astrahan et al. was deeper than the MS slot design (i.e., 1.4 mm versus 0.5 mm),
more photons interacted with the gold alloy and consequently the influence of gold-alloy

ρ and composition was more important for the slot design by Astrahan et al. However,
most of this effect is thought to be due to the gold-alloy composition as simulations of
only changing ρ for the MS slot design indicated minimal influence. Regardless,
changing gold-alloy ρ or composition for the MS or AS slot designs did not exceed the
5% threshold for importance.
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4.3.1.2. Slot Dimensions
For the MS slot design, Table 4.4 presents the influence of altering slot length,
width, and depth on CAX dose at 1, 2, 5, and 10 mm, respectively. Statistical
uncertainties (k=1) were <0.1%. While statistically significant variations in dose were
observed, none of these changes surpassed the 5% threshold considered to be
important for slot design variations.
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Table 4.4 The influence of slot length, width, and depth on dose variation along the CAX
at source distances of 1, 2, 5, and 10 mm for the measured plaque (MP) respectively. In
all cases, the dose perturbation due to these variations was less than 2.0%.
CAX

Δ slot length (mm)

Δ slot width (mm)

Δ slot depth (mm)

(mm)

–0.1

+0.1

–0.1

+0.1

+0.2

+0.3

–0.2

–0.1

+0.1

+0.2

1

1.000

1.000

1.006

1.013

1.015

1.016

0.991

0.995

1.015

1.013

2

1.001

1.000

1.004

1.013

1.015

1.017

0.997

0.999

1.008

0.999

5

0.994

1.000

1.004

1.012

1.015

1.016

1.008

1.005

1.002

0.987

10

1.014

1.001

1.006

1.012

1.016

1.018

1.016

1.010

1.000

0.983

4.3.1.3 Shifts of Seeds and Rods
The results in Table 4.5 had statistical uncertainties (k=1) <0.1%, and indicate
that CAX doses for 1<y<10 mm were within 5% of the MS CAX dose results. These
small differences were thought to be due to scatter conditions because of different slot
collimations. However, the CAX doses for the sMS slot design with the 125I-laden Ag rod
shifted 0.0994 mm away from the slot (z direction) exhibited higher doses (14.2% at 1
mm and 8.8% at 2 mm) than the MS design. These dose differences were thought to be
due to geometric effects, e.g., inverse-square, by positioning the radiation source closer
to the CAX point of interest. Increases of 16.4% at 1 mm and 9.3% at 2 mm would have
been expected due to geometry alone.
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Table 4.5 The influence of shifting the seed or rod on dose variation along the CAX at
source distances 1, 2, 5, and 10 mm respectively. Shifts in the x, y, and z directions
correspond to the transverse direction along the source midplane bisector, along the
source long axis, and outside the slot towards the ocular globe for MS slot respectively.
CAX
(mm)

Seed shift

Rod shift

x=0.0994 mm y=0.3495 mm z=0.0994 mm x=0.0994 mm y=0.3495 mm z=0.0994 mm

1

0.992

0.984

1.154

0.964

0.983

1.142

2

0.994

0.984

1.094

0.966

0.984

1.088

5

0.998

0.995

1.048

0.969

0.994

1.043

10

0.999

0.996

1.031

0.966

0.994

1.027

4.3.1.4. CAX Slot Dose Ratios
For the AS, 576S, nMS, and dMS slot designs, statistical uncertainties (k=1)
were <0.1%. The results in Table 4.6 indicate that CAX doses for 1<z<10 mm were
within 5% of the MS CAX dose results. The ratio of CAX doses of sMS and MS was the
same as reported in Table 4.5. Differences in CAX dose ratios for the other slot designs
were thought to be due to differing scatter conditions along the CAX because of
different slot collimations. All statistical uncertainties (k=1) for Table 4.6 were <0.1%.
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Table 4.6 The influence of altering the slot dimensions on the ratio of CAX doses of
different slot designs to the measured slot design.
CAX (mm)

AS / MS

576S / MS

sMS / MS

nMS / MS

dMS / MS

1

1.047

1.009

1.142

0.991

0.998

2

1.035

0.994

1.088

0.990

0.985

5

0.988

0.977

1.043

0.989

0.973

10

0.966

0.969

1.027

0.990

0.967
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4.3.2 Plaque Design
4.3.2.1. CAX Dose Comparison
For the plaque designs described in Table II, the results in Table VII indicate that
the CAX dose ratios to the MP plaque were within 5% except for the sMP plaque having
the rods shifted 0.0994 mm towards the ocular globe and for the dMP plaque having the
seeds shifted 0.51 mm away from the ocular globe. The large dose changes for these
two plaques were mainly thought to be due to changes in geometric effects by
positioning the radiation source closer and farther from the CAX point of interest,
respectively. It is evident that changing the slot length, width, and depth (i.e., 576P and
nMP) did not make large changes to the CAX dose ratio. Also included for comparison
is the CAX dose ratio of the PS software to the MP results. The planned dose of 85 Gy
to the tumor apex (Z=0.5 cm) using PS appears to deliver 88 Gy. The statistical
uncertainties (k=1) were <0.1% in contact with the globe, <0.2% at the tumor apex
(Z=5mm), and <0.7% at the opposite position in the eye from the plaque.
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Table 4.7 The influence of altering the slot design for the model EP917 eye plaque.
CAX dose ratios for are taken in comparison to the plaque using the reference
measured plaque design (MP). The 576P plaque has slots approximating values used
within the Plaque Simulator software and the PS v.5.7.6 results are taken from the
treatment planning system. The sMP plaque has the 125I-laden Ag rods shifted 0.0994
mm towards from the ocular globe; the nMP plaque has narrow slot lengths and widths;
and the dMP plaque has narrow slot lengths and widths with deeper slots and the seeds
shifted 0.51 mm shift away from ocular globe. Also included are the dMP’ results, being
the dMP results normalized (+25%) to match the MP dose at the tumor apex (Z=0.5
cm).
CAX
576P / MP

PS v.5.7.6 / MP

sMP / MP

nMP / MP

dMP / MP

dMP’ / MP

–1

0.951

0.928

1.343

0.983

0.306

0.380

0

0.947

0.921

1.050

0.972

0.581

0.722

1

0.970

0.965

1.032

0.985

0.665

0.826

2

0.979

0.966

1.030

0.988

0.718

0.891

5

0.984

0.967

1.028

0.989

0.804

1.000

10

0.974

0.996

1.022

0.987

0.830

1.034

15

0.972

0.996

1.017

0.988

0.833

1.035

20

0.979

0.998

1.015

0.988

0.845

1.047

22.6

0.990

0.997

1.020

0.986

0.842

1.049

(mm)

4.3.2.2 2D Dose Comparison
Dose distributions for the examined plaques did not vary substantially, except for
the dMP plaque design and the normalized dMP’ design. Fig. 4.4 depicts dose
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distributions on the XZ plane for some of these plaque designs, and also includes dose
distribution results adapted from the PS software for a side-by-side comparison with the
576P simulation results. The tumor volumes between the simulated environment (0.262
cm3) and the PS software (0.29 cm3) were similar, as also indicated graphically by the
tumor outlines in Fig. 4.4c and Fig. 4.4d, respectively. Based on this figure and Table
4.7, the CAX doses between the simulated are quite similar (within 3% at all distances
examined), and substantially differ only at locations far from the CAX. Ratios of dose
distributions on the XZ plane for the 576P and dMP’ plaque designs relative to the MP
design are shown in Fig. 4.4e and Fig. 4.4f, respectively. From these results in
comparison to the MP plaque design, it is evident that the dMP’ design minimizes the
dose gradient across the tumor while diminishing dose laterally with only small
increases in dose at the largest distances along the CAX (i.e., +5% for Z>2.0 cm).
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Figure 4.4 The ocular globe periphery (2.46 cm diameter) and inner surface are
indicated by the black circles with the tumor border similarly indicated. The tumor shape
from the Plaque Simulator software is included for comparison. Dose distributions on
the XZ plane for (a) the measured plaque design (MP), (b) the normalized results for the
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deep and narrow plaque design (dMP’), (c) the simulated plaque used in the Plaque
Simulator software (576P), and (d) results from the Plaque Simulator treatment planning
software (PS v.5.7.6) to deliver 85 Gy to the tumor apex (Z=0.5 cm) in 96 h. Comparing
the MP and dMP’ dose distributions, it is evident that 85 Gy isodose line is more
conformal for the dMP’ plaque design than the MP design. Also apparent is the
decreased dose gradient within the tumor and the increased dose conformity laterally
outside the eye, with slight dose increase along the plaque central axis, i.e., Z-axis.
Comparing the 576P and PS v.5.7.6 dose distributions, the central axis depth doses are
similar, but the PS v.5.7.6 results exhibit substantial dose lateral to the plaque (i.e.,
X>0.6cm and Z=0cm). The dose ratio (e) of the 576P plaque design to the MP
measured plaque design (576P/MP) is within 5% of unity throughout much of the ocular
geometry, decreasing substantially towards the plaque rim (i.e., X=0.7cm and
Z=0.1cm). The dose ratio (f) of the dMP’ plaque design to the MP measured plaque
design (dMP'/MP) shows greater variability, which may be interpreted through
comparing (a) and (b).

4.3.2.3 DVHs for the Plaques
The DVHs for the tumor, inner sclera, and outer sclera are depicted in Fig. 4.5,
and demonstrated the same trend as the CAX dose ratios in Table 4.7. When
considering the tumor DVH, it appears that there were no substantial differences among
the examined plaque designs except for the dMP having deep and narrow slots.
However, differences between the plaques were more pronounced for the inner and
outer sclera, albeit following the same trend as exhibited for the tumor.
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Figure 4.5 DVHs for the (a) tumor, (b) inner sclera, and (c) outer sclera for the model
EP917 eye plaque loaded with model IAI-125A 125I seeds. Consistently, the sMP plaque
having the 125I-laden Ag rods shifted 0.0994 mm towards from the ocular globe had the
largest values for all three volumes, with the reference measured plaque (MP), narrow
plaque (nMP), simulated Plaque Simulator plaque design (576P), results from the
Plaque Simulator treatment planning software (PS v.5.7.6), and the deep and narrow
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plaque (dMP) following consecutively. Also included are the dMP’ results, being the
dMP results normalized (+25%) to match the MP dose at the tumor apex (Z=0.5 cm).

Ratios of tumor D10 values for the examined plaque designs to the MP design are
given in Table 4.8. To understand these ratios in absolute dose, the MP D10 values for
the tumor, inner sclera, and outer sclera were 242.3, 270.4, and 460.0 Gy, respectively.
For example, tumor D10 for the dMP design was 130.3 Gy. In comparison to the
simulated PS plaque (i.e., 576P), the D10 dose ratio determined using the PS software
(i.e., PS v.5.7.6) was 2% higher. The ratio of D10 for the outer sclera to the inner sclera
was 1.70 on average (i.e., 1.70 for MP, 1.53 for 576P, 1.89 for sMP, and 1.66 for nMP)
except for the dMP design, which had a ratio of only 1.027. Thus, the dMP design
appeared to provide substantial reduction in the high-dose gradient over the ocular
globe.
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Table 4.8 The D10 ratios for various plaque designs to the MP plaque design for the
tumor, inner sclera, and outer sclera. Ratios to the measured plaque design (MP) are
taken for the simulated Plaque Simulator plaque design (576P), results from the Plaque
Simulator treatment planning software (PS v.5.7.6), a simulated plaque having the 125Iladen Ag rods shifted 0.0994 mm towards from the ocular globe (sMP), a simulated
plaque having narrow slot lengths and widths (nMP), and a simulated plaque having
narrow slot lengths and widths with deeper slots and the seeds shifted 0.51 mm shift
away from ocular globe (dMP). The dMP’ plaque results are the dMP results normalized
(+25%) to match the MP dose at the tumor apex (Z=0.5 cm). The tumor D10 ratio (i.e.,
0.931) for the Plaque Simulator software results to the reference measured plaque
design is provided (PS v.5.7.6 / MP). However, it was not feasible to enter the scleral
geometries simulated using Monte Carlo methods into the Plaque Simulator software,
and thus no ratios are provided.
Ratio

Tumor

Inner sclera

Outer sclera

576P / MP

0.912

0.905

0.814

PS v.5.7.6 / MP

0.931

---

---

sMP / MP

1.026

1.045

1.163

nMP / MP

0.962

0.949

0.927

dMP / MP

0.538

0.486

0.293

dMP’ / MP

0.698

0.631

0.380
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4.4. Discussion

Based on observations during routine clinical practice, it appeared that the design
of the EP917 plaques delivered to our center differed from that reported by Astrahan et
al. and as used in the PS software. Given their disagreement and the lack of literature
independently evaluating this type of plaque, we hypothesized that plaque design
differences would cause substantial dosimetric differences. The measured slot shape
was rounded with rounded ends and had an average depth of 0.46±0.16 mm, which
differed significantly from Astrahan et al. and the reported depth in the PS software.
When keeping slot length and width fixed and changing the slot depth
(consequently moving the seed 0.51 mm farther from the sclera), the dose ratio of
dMP/MP by nMP/MP on the CAX at Z=–1 mm (indicative of the maximum outer scleral
doses) was 0.306/0.983 or 0.311 (see Table 4.7). For a slot depth change of 0.51 mm,
this dose ratio corresponds to –20% per 0.1 mm in slot depth. Conversely, when moving
the seed in the opposite direction (i.e., towards the sclera) and keeping the plaque
distance fixed, the dose ratio of sMP/MP at the same location was 1.343, for dose
change of +35% per 0.1 mm. From the perspective of the DVH outer sclera D10 metric
(see Table 4.8), these changes were –20% per 0.1 mm and +16% per 0.1 mm,
respectively, and –11% per 0.1 mm and +2.6% per 0.1 mm for the tumor D10 metric,
respectively. While the change in slot depth would occur through designs changes to
the plaque slots, prevention of the dose increases would require brachytherapy seeds
not having dynamic internal components.31
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Dose results between the 576P plaque and the PS v.5.7.6. TPS results were
generally in good agreement, substantially differing only at locations far from the CAX,
and may have been due to the approximation of the PS slot in the simulation geometry.
Table 4.8 shows that plaque design did not change tumor D10 by more than 10% except
for dMP and dMP’. When considered in combination with Fig. 4.4f, it is clear that plaque
design changes require concern for both relative changes in the dose distribution and
absolute changes in delivered dose.
Given the exquisite sensitivity of dose delivery to brachytherapy plaque design, it
is crucial that the acceptance testing procedure for eye plaques quantitatively compare
the plaque manufacturer specifications for the slot shape, dimensions, and positions on
the plaque with measurements performed by the medical physicist preceding clinical
use. While dosimetric changes greater than 5% have been observed for plaque design
changes of just 0.1 mm, accurate measurements smaller than this value may be too
challenging for the majority of clinical medical physicists as their purview in
brachytherapy is generally source-strength measurements. 71 Therefore, we suggest
that a dimensional tolerance of 0.1 mm used to evaluate such medical devices.
Results of the current study differ from the reference publication by Astrahan et al.
primarily in slot depth. Astrahan et al. reported a depth of 1.4 mm, while our
measurements reveal a range of 0.46±0.16 mm (k=1). Given the dramatic difference in
results between the MP and dMP plaque designs (even when normalized as in the dMP’
case), slot depth (when keeping other aspects fixed, such as slot width and length) is a
crucial

feature

for

eye

plaques

alleging

seed

collimation.

Without

proper

characterization of the slot (and plaque) geometry, TPS results are not meaningful.
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As shown in Table 4.5, Fig. 4.4, and Fig. 4.5, the model EP917 plaque appears to
be less conformal than the design used in the PS software. Marwaha et al.48and Berry
et al.55report favorable clinical results for episcleral brachytherapy. Both publications
depict dose distributions for the model EP917 plaque, indicating similar shapes to Fig.
4.4d. Consequently, their clinical findings may be better than reported given the
delivered doses were higher than indicated by the TPS results using PS.
With only a single slot loaded, Lesperance et al. 72 reported a 2.5 % increase in
scleral dose when compared to the same arrangement without slot. A similar result
(+3%) was reported by Aryal and Molloy. 73Lesperance et al. compared doses with MC
methods to doses expected when using the AAPM TG-43 dose calculation formalism for
a fully-loaded round-plaque containing 15 seeds and the 1.4-mm deep slot design by
Astrahan et al. It appears that Lesperance et al. observed this dose ratio to substantially
diminish for scleral distances less than 0.4 cm. This observation is supported by their
Fig. 7e.
There were several limitations of the current study. The manufacturer did not
provide the proprietary composition of the gold-alloy material. Further, the exact slot
shape used in PS to perform treatment planning for the model EP917 plaque could not
be fully simulated in the current study because of overlap at the slot corners. These
limitations were mitigated by evaluating the dosimetric influence of gold-alloy
composition and slot design. To keep the current study manageable, only one tumor
size and shape was examined with dimensions based on that used in the joint
AAPM+ABS TG-129 report. 74 Similarly, the influence of replacing the surrounding water
environment with tissue as examined by Lesperance et al. was not performed.72Another
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study limitation was to restrict the dose evaluation metric to D10. While differences
among the plaques increased with higher dose, the relative behavior of the different
designs did not substantially change for higher dose metrics.
The scope of the current study may be extended with additional research. This
would include choosing sources different than the model IAI-125I

125

I seed. Another

topic would include a comparison between COMS-style plaques and the EP917 plaque
to evaluate tumor and scleral doses, as the measured EP917 slot depths were
substantially less than reported by Astrahan et al.

4.5. Conclusion
Extensive measurements reveal that the slot shape reported by Astrahan et al.
and the overall plaque design used in the PS software are not representative of the
physical devices used for patient treatments. The physical plaques place the seeds in
direct contact with the outer sclera and deliver substantially higher doses than indicated
by the PS TPS. Radiation transport simulations analyzing dose-distribution sensitivity to
plaque design showed that plaques with deeper slots provide superior dose uniformity
and homogeneity to the tumor without compromising the scleral dose. A dosimetric
analysis on the sensitivity of slot and plaque design revealed that small (i.e., 0.1 mm)
physical changes can cause up to 35% changes in dose delivery. Additional research is
needed to optimize plaque design and subsequently permit accurate treatment planning
and clinical implementation.
Copyright © Prakash Aryal 2014
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CHAPTER 5 SUMMARY AND CONCLUSIONS
5.1 Proposed TG-43 Dosimetry Parameters
Existing consensus data (i.e., TG-43 dosimetry parameters) for some brachytherapy
sources are based in part on outdated MC codes. The MCNP package has been
revised to include updated photon cross-section libraries, variance reduction
techniques, and other improvements since its 1987 release. The AdvantageTM model
IAI-125A 125I brachytherapy seed was selected as a focus of this study.
Air-kerma rates, the dose-rate constant, Λ, radial dose function, gL(r), and the 2D
anisotropy function, F(r, θ), were calculated for 12 simulation conditions. These
parameters were compared with the published literature and TG-43U1S1 consensus
data. Results showed that Λ values by Solberg et al., Meigooni et al., Taylor and
Rogers, and the 2007 AAPM TG-43U1S1 report were 4.3%, 6.2%, 0.3% and 6.3%
higher than our Λ value, respectively. The proposed gL(r) values differed by >10% for
r>5 cm compared to Solberg et al. and Meigooni et al., respectively. However, the
proposed values are within 2% of Taylor and Rogers and within 0.5 % for 0.5 < r < 10
cm.
F(r,θ) values from our proposed standard were also compared to Solberg et al.,
Meigooni et al., Taylor and Rogers, and Kennedy et al. Large variations were noticed at
θ < 20°. At F (1, 10°), Solberg et al., Meigooni et al. and Taylor and Rogers reported
values that were <2%, 37% and 10% higher than our current study respectively.
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5.2 Dosimetric Influence of Slot and Plaque Design of the EP917 Eye Plaque

The EP917 plaque was proposed by Astrahan et al. These plaques were
purported to deliver more conformal and homogeneous doses to the tumor while
sparing normal structures, such as the sclera, due to collimation from a deep slot
design. But upon acquiring three model EP917 plaques for clinical use, we found that
the slots depths and design were different than that described by Astrahan et al. and
also different than the design within the PS treatment planning software. An
investigation was performed to accurately measure the eye plaque slots and overall
design to resolve the physical discrepancies. MC methods were used to determine the
dosimetric influence of the eye plaque design variations.
Measurements revealed that the slot shape reported by Astrahan et al. and the
overall plaque design used in the PS software were not representative of the physical
devices used for patient treatments. The physical plaques place the seeds in direct
contact with the outer sclera and deliver substantially higher doses than indicated by the
PS TPS. Radiation transport simulations analyzing dose-distribution sensitivity to plaque
design showed that plaques with deeper slots provided superior dose uniformity and
homogeneity to the tumor without compromising the scleral dose. A dosimetric analysis
of the sensitivity of slot and plaque design revealed that small (i.e., 0.1 mm) physical
changes can cause up to 35% changes in dose delivery. Additional research is needed
to optimize plaque design and subsequently permit accurate treatment planning and
clinical implementation.
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5.3 Future work
This work was limited to the EP917 plaque design and 125I (model IAI-125A)
seed. Future work of should extend this study to other radionuclide seed models (such
as 103Pd and 131Cs) and make quantitative comparisons of the model EP917 plaque with
the standardized COMS eye plaques for guiding clinical decision making.

Copyright © Prakash Aryal 2014
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APPENDIX
List of abbreviations
AAPM: American Association of Physicists in Medicine
cGy: centi Gray
COMS: Collaborative Ocular Melanoma Study
HDR: High Dose-Rate
LDR: Low Dose-Rate
MCNP5: Monte Carlo N-particle code, version 5
NIST: National Institute of Standards and Technology
P,E: photons, electrons
P: photons
TG-43: Task Group number 43
TTB: Thick Target Bremsstrahlung
U: Unit of air-kerma strength
USC: University of Southern California
WAFAC: Wide Angle Free Air Chamber
TG43U1: 2004 update to 1995 TG-43 report
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